<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">97373</article-id><article-id pub-id-type="doi">10.7554/eLife.97373</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.97373.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>TAK1-mediated phosphorylation of PLCE1 represses PIP2 hydrolysis to impede esophageal squamous cancer metastasis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ju</surname><given-names>Qianqian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7561-1058</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sheng</surname><given-names>Wenjing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Meichen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Liucheng</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiaoyu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fang</surname><given-names>Wentao</given-names></name><email>vwtfang@hotmail.com</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shi</surname><given-names>Hui</given-names></name><email>shihui1@shchest.org</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sun</surname><given-names>Cheng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8411-4619</contrib-id><email>suncheng1975@ntu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02afcvw97</institution-id><institution>Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education; NMPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products; School of Medicine, Nantong University</institution></institution-wrap><addr-line><named-content content-type="city">Nantong</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02afcvw97</institution-id><institution>Laboratory Animal Center, Nantong University</institution></institution-wrap><addr-line><named-content content-type="city">Nantong</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220qvk04</institution-id><institution>Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ali</surname><given-names>Sameh</given-names></name><role>Reviewing Editor</role><aff><institution>Children's Cancer Hospital Egypt</institution><country>Egypt</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>23</day><month>04</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP97373</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-03-21"><day>21</day><month>03</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-27"><day>27</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.22.586256"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-06-03"><day>03</day><month>06</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.97373.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-09-10"><day>10</day><month>09</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.97373.2"/></event></pub-history><permissions><copyright-statement>© 2024, Ju et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Ju et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-97373-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-97373-figures-v1.pdf"/><abstract><p>TAK1 is a serine/threonine protein kinase that is a key regulator in a wide variety of cellular processes. However, the functions and mechanisms involved in cancer metastasis are still not well understood. Here, we found that TAK1 knockdown promoted esophageal squamous cancer carcinoma (ESCC) migration and invasion, whereas TAK1 overexpression resulted in the opposite outcome. These in vitro findings were recapitulated in vivo in a xenograft metastatic mouse model. Mechanistically, co-immunoprecipitation and mass spectrometry demonstrated that TAK1 interacted with phospholipase C epsilon 1 (PLCE1) and phosphorylated PLCE1 at serine 1060 (S1060). Functional studies revealed that phosphorylation at S1060 in PLCE1 resulted in decreased enzyme activity, leading to the repression of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis. As a result, the degradation products of PIP2 including diacylglycerol (DAG) and inositol IP3 were reduced, which thereby suppressed signal transduction in the axis of PKC/GSK-3β/β-Catenin. Consequently, expression of cancer metastasis-related genes was impeded by TAK1. Overall, our data indicate that TAK1 plays a negative role in ESCC metastasis, which depends on the TAK1-induced phosphorylation of PLCE1 at S1060.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>TAK1</kwd><kwd>PLCE1</kwd><kwd>esophageal squamous cancer</kwd><kwd>PIP2</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>32271193</award-id><principal-award-recipient><name><surname>Sun</surname><given-names>Cheng</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007219</institution-id><institution>Natural Science Foundation of Shanghai</institution></institution-wrap></funding-source><award-id>21ZR1449800</award-id><principal-award-recipient><name><surname>Shi</surname><given-names>Hui</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100017950</institution-id><institution>Scientific Project from Shanghai Municipal Health Commission</institution></institution-wrap></funding-source><award-id>202240015</award-id><principal-award-recipient><name><surname>Shi</surname><given-names>Hui</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Postgraduate Research &amp; Practice Innovation Program of Jiangsu Province</institution></institution-wrap></funding-source><award-id>KYCX23_3411</award-id><principal-award-recipient><name><surname>Ju</surname><given-names>Qianqian</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>TAK1 plays a negative role in esophageal squamous cancer cell metastasis, which depends on the TAK1-induced phosphorylation of PLCE1 at S1060 and subsequent inhibition of PIP2 hydrolysis.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Esophageal cancer (EC) is the seventh most common malignancy worldwide, with more than 600,000 new cases diagnosed annually (<xref ref-type="bibr" rid="bib45">Sung et al., 2021</xref>). The primary histological subtypes of EC include esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (<xref ref-type="bibr" rid="bib22">He et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">Lagergren et al., 2017</xref>). ESCC is a major subtype of EC in China, accounting for more than 90% of EC (<xref ref-type="bibr" rid="bib22">He et al., 2021</xref>). The early diagnosis rate of ESCC is very low owing to the lack of specific biomarkers. Thus, most patients are found to be in locally advanced or metastatic stages when they are diagnosed. The 5-year survival rate is approximately 15–25% (<xref ref-type="bibr" rid="bib36">Pennathur et al., 2013</xref>). In recent decades, although therapeutic strategies have made great progress toward ESCC, recurrence and metastasis remain significant challenges (<xref ref-type="bibr" rid="bib33">Mao et al., 2021</xref>). Therefore, there is an urgent need to deeply understand the mechanisms involved in cell metastasis, and thus try to explore new druggable targets for treating ESCC.</p><p>Transforming growth factor β-activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) family, is encoded by the gene <italic>Map3k7</italic>. As a serine/threonine protein kinase, TAK1 has been shown to play an integral role in inflammatory signal transduction through multiple pathways (<xref ref-type="bibr" rid="bib38">Sakurai, 2012</xref>). TAK1 is involved in a wide variety of cellular processes, including cell survival, cell migration and invasion, inflammation, immune regulation, and tumorigenesis (<xref ref-type="bibr" rid="bib9">Cho et al., 2021</xref>; <xref ref-type="bibr" rid="bib34">Mukhopadhyay and Lee, 2020</xref>). Although the role of TAK1 has been widely studied, its precise role remains controversial. For example, by acting as a tumor suppressor, TAK1 has been shown to negatively associated with tumor progression in several human cancers including prostate cancer (<xref ref-type="bibr" rid="bib23">Huang et al., 2021</xref>), hepatocellular carcinoma (HCC) (<xref ref-type="bibr" rid="bib46">Tan et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Wang et al., 2021</xref>), cervical cancer (<xref ref-type="bibr" rid="bib17">Guan et al., 2017</xref>), and certain blood cancers (<xref ref-type="bibr" rid="bib18">Guo et al., 2019</xref>). In contrast, TAK1 promotes tumor progression in a variety of human cancers, including colon, ovarian, lung, and breast cancers (<xref ref-type="bibr" rid="bib3">Augeri et al., 2016</xref>; <xref ref-type="bibr" rid="bib5">Cai et al., 2014</xref>; <xref ref-type="bibr" rid="bib57">Xu et al., 2022</xref>). These aforementioned findings indicate that TAK1 plays a dual role in tumor initiation, progression, and metastasis. In our previous study, TAK1 has been shown to phosphorylate RASSF9 at serine 284 to inhibit cell proliferation by targeting the RAS/MEK/ERK axis in ESCC (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). To date, there have been no reports on the precise role of TAK1 in ESCC metastasis.</p><p>Phospholipase C epsilon 1 (PLCE1) is encoded by the <italic>Plce1</italic> gene on chromosome 10q23 in human and belongs to the phospholipase C (PLC) family (<xref ref-type="bibr" rid="bib14">Fukami et al., 2010</xref>; <xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>). Like other PLC family members, PLCE1 is composed of a PLC catalytic domain, PH domain, EF domain, and C2 domain. In addition, PLCE1 contains unique regions, two C-terminal Ras association (RA) domains and an N-terminal CDC25-homology domain (<xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>). Once activated, PLCE1 is essential for intracellular signaling by catalyzing the hydrolysis of membrane phospholipids such as phosphatidylinositol 4,5-bisphosphate (PIP2), in order to produce two important secondary messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which further trigger IP3-dependent calcium ion (Ca<sup>2+</sup>) release from the endoplasmic reticulum and PKC activation (<xref ref-type="bibr" rid="bib14">Fukami et al., 2010</xref>; <xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>). Accumulating evidence has shown that PLCE1 promotes cell growth, migration, and metastasis in multiple human cancers, including hepatocellular carcinoma, non-small-cell lung cancer, head and neck cancer, bladder cancer, gastric cancer, and prostate cancer (<xref ref-type="bibr" rid="bib1">Abnet et al., 2010</xref>; <xref ref-type="bibr" rid="bib11">Fan et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Liao et al., 2017</xref>; <xref ref-type="bibr" rid="bib32">Ma et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Ou et al., 2010</xref>; <xref ref-type="bibr" rid="bib52">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Yue et al., 2019</xref>). However, whether and how PLCE1 affects cancer metastasis in ESCC remain largely unknown.</p><p>In the present study, we have examined the potential role of TAK1 in ESCC metastasis. We found that TAK1 negatively regulates cell migration and invasion in ESCC, and that PLCE1 is a downstream target of TAK1. TAK1 phosphorylates PLCE1 at serine 1060 (S1060) to inhibit its enzymatic activity, leading to decreased IP3 and DAG levels, both of which are products of PLCE1 catalyzed reactions. As a result, IP3/DAG triggered signal transduction in the axis of PKC/GSK-3β/β-Catenin was blunted. All these effects induced by TAK1 resulted in the repression of cell migration and invasion in ESCC.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TAK1 negatively regulates ESCC migration and invasion</title><p>In our previous study, we showed that TAK1 expression was reduced in esophageal squamous tumor tissues, and that TAK1 inhibits ESCC proliferation (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). To examine whether TAK1 affects the epithelial-mesenchymal transition (EMT) process in ESCC, we increased TAK1 expression in ECA-109 cells by transfecting a plasmid expressing <italic>Map3k7</italic> (TAK1 gene name) and confirmed the overexpression of TAK1 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Owing to the promising role of epidermal growth factor (EGF) in EMT (<xref ref-type="bibr" rid="bib31">Lu et al., 2003</xref>), it has been used to trigger EMT in ESCC. As shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>, EGF treatment induced a spindle-shaped morphology in ECA-109 cells, which was markedly prevented by TAK1. These data implied that TAK1 is a negative regulator of EMT in ESCC. To address this hypothesis, we performed a transwell assay and found that TAK1 repressed the migration and invasion of ECA-109 cells (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). The wound healing assay further confirmed the negative effects of TAK1 on cancer cell migration (<xref ref-type="fig" rid="fig1">Figure 1D</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Next, we examined whether TAK1 affects EMT-related gene expression. Our data showed that TAK1 increased E-cadherin and ZO-1, two epithelial molecules, whereas mesenchymal molecules such as N-cadherin, Vimentin, and ZEB1 were reduced by TAK1 (<xref ref-type="fig" rid="fig1">Figure 1E</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). The quantitative real time-PCR (qRT-PCR) data confirmed these changes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>TAK1 negatively regulates esophageal squamous cell carcinoma (ESCC) migration and invasion.</title><p>(<bold>A</bold>) Increased expression of TAK1 in ECA-109 cells transfected with a plasmid expressing <italic>Map3k7</italic>. (<bold>B</bold>) Increased expression of TAK1 inhibits the morphological changes to form spindle-shaped mesenchymal cells induced by epidermal growth factor (EGF) (100 ng/ml) in ECA-109. Scale bar = 100 µm. (<bold>C</bold>) Increased expression of TAK1 inhibits cell migration and invasion in ECA-109 cells. Cell migration and invasion were analyzed by transwell assay. n=4 biologically independent replicates. (<bold>D</bold>) Wound healing assay showing cell migration was attenuated by TAK1. n=5 biologically independent replicates. (<bold>E</bold>) TAK1 decreased mesenchymal marker gene expression, while increased the expression of epithelial markers. ECA-109 cells were transfected with the plasmid carrying Map3k7. 24 hr post-transfection, protein samples were prepared and subjected to western blot. Actin was used as a loading control. (<bold>F</bold>) Knockdown of TAK1 increased the expression of F-Actin. ECA-109 cells were transfected with Map3k7 siRNA. 72 hr post-transfection, cells were subjected to immunofluorescence analysis using an anti-F-Actin antibody (red). Hoechst was used to stain the nucleus (blue). Scale bar = 10 µm. (<bold>G</bold>) TAK1 knockdown induces spindle-shaped mesenchymal cell morphology in ECA-109 cells. Scale bar = 100 µm. (<bold>H</bold>) Reduced expression of TAK1 promotes cell migration and invasion. ECA-109 cells were transfected with Map3k7 siRNA. 72 hr post-transfection, cell migration and invasion were analyzed by transwell assay. n=5 biologically independent replicates. (<bold>I</bold>) Knockdown of TAK1 increases mesenchymal protein marker expression and decreases epithelial protein marker expression. Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>TAK1 negatively regulates esophageal squamous cell carcinoma (ESCC) migration and invasion.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig1">Figure 1A, E, and I</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig1">Figure 1A, E, and I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>TAK1 represses cell migration in ECA-109 cells<italic>.</italic></title><p>Cells were transfected with a plasmid expressing Map3k7. 24 or 48 hr post-transfection, cells were subjected to transwell (<bold>A</bold>) and wound healing assay (<bold>B</bold>). Scale bar = 500 µm (<bold>A</bold>) and 100 µm (<bold>B</bold>). (<bold>C</bold>) Quantified protein expression based on western blot data in <xref ref-type="fig" rid="fig1">Figure 1E</xref>. n=3 biologically independent replicates. (<bold>D</bold>) TAK1 decreased mesenchymal marker gene expression, while increased the expression of epithelial markers. Gene expression was analyzed by quantitative real time-PCR (qRT-PCR), and <italic>Gapdh</italic> was used as a house-keeping gene. n=4 biologically independent replicates. Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001<italic>.</italic></p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>TAK1 represses cell migration in ECA-109 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>TAK1 silencing promotes esophageal squamous cell carcinoma (ESCC) migration and invasion.</title><p>(<bold>A–C</bold>) Knockdown of TAK1 in ECA-109 cells promotes cell migration and invasion analyzed by transwell (<bold>A</bold>) and wound healing (<bold>B</bold>) assays. Scale bar = 500 µm (<bold>A</bold>) or 100 µm (<bold>B</bold>). (<bold>C</bold>) Quantitative analysis of the western blot data as shown in <xref ref-type="fig" rid="fig1">Figure 1I</xref>. n=3 biologically independent replicates. (<bold>D</bold>) Reduced expression of TAK1 in ECA-109 cells increases mesenchymal marker gene expression, while decreases epithelial marker gene expression. Gene expression was analyzed by quantitative real time-PCR (qRT-PCR), and <italic>Gapdh</italic> was used as a house-keeping gene. n=4 biologically independent replicates. Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001<italic>.</italic></p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>TAK1 silencing promotes esophageal squamous cell carcinoma (ESCC) migration and invasion.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>TAK1 knockdown facilitates esophageal squamous cell carcinoma (ESCC) migration and invasion.</title><p>(<bold>A–B</bold>) Knockdown of TAK1 by <italic>Map3k7</italic> shRNA. ECA-109 cells were transduced with lentivirus bearing <italic>Map3k7</italic> shRNA (LV-<italic>Map3k7</italic> shRNA) or NC shRNA (LV-NC). 48 hr post-transduction, cells were harvested for analyzing TAK1 expression by quantitative real time-PCR (qRT-PCR) (<bold>A</bold>) and western blot (<bold>B</bold>). n<italic>=</italic>3 biologically independent replicates. (<bold>C–E</bold>) Decreased <italic>expression of</italic> TAK1 facilitates cell migration and invasion. ECA-109 cells were transduced with LV-<italic>Map3k7</italic> shRNA or LV-NC. 48 hr post-transduction, cells were subjected to transwell (<bold>C, D</bold>) or wound healing (<bold>E</bold>) assay. n=5 biologically independent replicates. Scale bar = 500 µm (<bold>C</bold>); scale bar = 100 µm (<bold>E</bold>). (<bold>F</bold>–<bold>G</bold>) Reduced expression of TAK1 increases mesenchymal marker expression and decreases epithelial marker expression. n=3 biologically independent replicates. (<bold>H</bold>) Reduced expression of TAK1 in ECA-109 cells affects epithelial-mesenchymal transition (EMT) related gene expression. Protein levels were analyzed by western blot, and Actin was used as a loading control. Gene expression was detected by qRT-PCR, and <italic>Gapdh</italic> was used as a house-keeping gene. n=4 biologically independent replicates. Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>TAK1 knockdown facilitates esophageal squamous cell carcinoma (ESCC) migration and invasion.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig1-figsupp3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s3sdata2"><label>Figure 1—figure supplement 3—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B and F</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig1-figsupp3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s3sdata3"><label>Figure 1—figure supplement 3—source data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B and F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig1-figsupp3-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>TAK1 knockout accelerates esophageal squamous cell carcinoma (ESCC) migration and invasion.</title><p>(<bold>A–B</bold>) TAK1 expression was decreased by Map3k7 gRNA in ECA-109 cells. TAK1 knockout was achieved by CRISPR-Cas9. (B–D) Knockout of TAK1 expression in ECA-109 cells accelerates cell migration and invasion as analyzed by transwell (<bold>B, C</bold>) and wound healing (<bold>D</bold>) assays. Scale bar = 500 µm (<bold>B</bold>); scale bar = 100 µm (<bold>D</bold>). (<bold>E</bold>–<bold>F</bold>) Loss of TAK1 increases mesenchymal protein marker expression and reduces epithelial protein marker expression. ECA-109 cells were treated with Map3k7 gRNA, and then cells were harvested for western blot analysis. n=3 biologically independent replicates. (<bold>G</bold>) Knockout of TAK1 expression in ECA-109 cells alters epithelial-mesenchymal transition (EMT) related gene expression as analyzed by quantitative real time-PCR (qRT-PCR). <italic>Gapdh</italic> was used as a house-keeping gene. n=4 biologically independent replicates. Protein levels were analyzed by western blot, and Actin was used as a loading control. Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p><p><supplementary-material id="fig1s4sdata1"><label>Figure 1—figure supplement 4—source data 1.</label><caption><title>TAK1 knockout accelerates esophageal squamous cell carcinoma (ESCC) migration and invasion.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig1-figsupp4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s4sdata2"><label>Figure 1—figure supplement 4—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A and E</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig1-figsupp4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s4sdata3"><label>Figure 1—figure supplement 4—source data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A and E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig1-figsupp4-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Inhibition of TAK1 potentiates cell migration and invasion in ECA-109 cells.</title><p>Cells were treated with (5Z)-7-oxozeaenol (Oxo; 10 µM), or NG25 (10 µM), or Takinib (10 µM) for 24 hr, and then cell morphology, migration, and invasion were analyzed. (<bold>A</bold>) Inhibition of TAK1 promotes morphological changes to form spindle-shaped mesenchymal cells in ECA-109 cells. Scale bar = 100 µm. (<bold>B–E</bold>) Inhibition of TAK1 promotes cell migration and invasion in ECA-109 cells. Cell migration and invasion were analyzed by transwell (<bold>B, C</bold>) and wound healing (<bold>D, E</bold>) assays. Scale bar = 500 µm (<bold>B</bold>); scale bar = 100 µm (<bold>D</bold>). n=5 biologically independent replicates. Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. <italic>*</italic>p&lt;0.05 and <italic>***</italic>p<italic>&lt;</italic>0.001<italic>.</italic></p><p><supplementary-material id="fig1s5sdata1"><label>Figure 1—figure supplement 5—source data 1.</label><caption><title>Inhibition of TAK1 potentiates cell migration and invasion in ECA-109 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig1-figsupp5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig1-figsupp5-v1.tif"/></fig></fig-group><p>Next, we performed loss-of-function experiments to examine the effect of TAK1 on ESCC cell migration and invasion. The knockdown efficiency of <italic>Map3k7</italic> siRNA on TAK1 expression has been reported previously (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). As EMT involves dynamic and spatial regulation of the cytoskeleton (<xref ref-type="bibr" rid="bib12">Fife et al., 2014</xref>; <xref ref-type="bibr" rid="bib28">Li and Wang, 2020</xref>), we analyzed the expression of F-Actin by immunofluorescence. As shown in <xref ref-type="fig" rid="fig1">Figure 1F</xref>, TAK1 knockdown induced F-Actin expression. TAK1 knockdown promoted a spindle-shaped mesenchymal morphology in ECA-109 cells (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). In accordance with these changes, cell invasion and migration were stimulated, as evidenced by data from the wound healing and transwell assays (<xref ref-type="fig" rid="fig1">Figure 1H</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A and B</xref>). The epithelial markers including E-cadherin and Claudin-1 were found to have decreased by TAK1 knockdown, whereas mesenchymal markers N-cadherin, Vimentin, Snail, and Slug were increased (<xref ref-type="fig" rid="fig1">Figure 1I</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). At the mRNA level, <italic>Cdh1</italic> and <italic>Cldn1</italic> were downregulated by TAK1 knockdown, whereas <italic>Cdh2</italic> and <italic>Snail1</italic> were upregulated (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). To verify the effect of TAK1 knockdown on cell migration and invasion, we downregulated TAK1 expression using a lentivirus carrying <italic>Map3k7</italic> shRNA (LV-<italic>Map3k7</italic> shRNA) (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A and B</xref>). In LV-<italic>Map3k7</italic> shRNA-transduced cells, cell migration and invasion were clearly increased (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C–E</xref>). The epithelial markers E-cadherin, ZO-1, and Claudin-1 were repressed by TAK1 knockdown, whereas mesenchymal markers N-cadherin, Slug, and ZEB-1 were activated (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3F and G</xref>). Our qRT-PCR data showed similar changes in these EMT genes (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3H</xref>). Additionally, TAK1 knockdown was accomplished by CRISPR-Cas9 using <italic>Map3k7</italic> guide RNA (gRNA) (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>). Again, we observed that cell migration and invasion were enhanced by <italic>Map3k7</italic> gRNA (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B-D</xref>). The expression of E-cadherin, ZO-1, and Claudin-1 was inhibited by <italic>Map3k7</italic> gRNA, whereas the expression of N-cadherin, Vimentin, Snail, and Slug was activated (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4E and F</xref>). Similar changes in these EMT-related gene expression were observed using qRT-PCR (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4G</xref>). Furthermore, we inhibited TAK1 activity using Oxo, NG25, or Takinib and observed that all of these treatments induced morphological changes in ECA-109 cells from round shapes to spindle-like shapes (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5A</xref>). Cell migration and invasion were also stimulated by TAK1 inhibition (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5B–E</xref>). Taken together, these findings indicate that TAK1 negatively regulates ESCC migration and invasion.</p></sec><sec id="s2-2"><title>TAK1 phosphorylates PLCE1 at serine 1060</title><p>These aforementioned data clearly show that TAK1 negatively regulates the cell migration and invasion of ESCC. To reveal the underlying mechanism, we performed co-immunoprecipitation combined with mass spectrometry in order to identify potential downstream targets of TAK1. As previously reported, 24 proteins were phosphorylated in the immunocomplex (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). Of these, phospholipase C epsilon 1 (PLCE1) has attracted our attention because of its essential role in cell growth, migration, and metastasis in various human cancers (<xref ref-type="bibr" rid="bib1">Abnet et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Gu et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>; <xref ref-type="bibr" rid="bib51">Wang et al., 2010</xref>). According to the mass spectrometry data, the serine residue at position 1060 (S1060) in PLCE1 was phosphorylated (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Currently, there is no antibody against phosphorylated PLCE1 at S1060 (p-PLCE1 S1060), we therefore generated an antibody to detect p-PLCE1 S1060. To verify antibody specificity, S1060 in PLCE1 was mutated to alanine (S1060A). As shown in <xref ref-type="fig" rid="fig2">Figure 2B</xref>, wildtype (WT) PLCE1 was phosphorylated by TAK1 at S1060, whereas PCLE1 S1060A was resistant to TAK1-induced phosphorylation at S1060. Moreover, the p-PLCE1 S1060 induced by TAK1 was weakened by(5Z)-7-oxozeaenol (Oxo), a potent inhibitor of TAK1 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Notably, phosphorylated TAK1 (p-TAK1) markedly decreased in the presence of Oxo, indicating that TAK1 was inhibited (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). To further confirm these findings, other TAK1 inhibitors, such as Takinib and NG25, were used, and similar changes in p-PLCE1 and p-TAK1 were observed (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). As for endogenous p-PLCE1 S1060, it was increased and decreased, respectively, by TAK1 overexpression and knockdown (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>). Moreover, the in vitro kinase assay showed that PLCE1 was phosphorylated by TAK1 at serine 1060 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Collectively, these results indicate that PLCE1 is a downstream target of TAK1, and that PLCE1 S1060 is phosphorylated by TAK1. To further confirm this notion, we analyzed TAK1 and p-PCLE1 expression in clinical samples. As shown in <xref ref-type="fig" rid="fig2">Figure 2F</xref>, TAK1 expression was reduced in tumor tissues compared to that in their respective adjacent normal tissues. In accordance with these changes in TAK1, p-PLCE1 levels were also decreased in tumor tissues (<xref ref-type="fig" rid="fig2">Figure 2G</xref>) Pearson’s correlation tests showed that TAK1 expression was positively correlated with p-PLCE1 expression (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). These changes in TAK1 and p-PLCE1 levels were confirmed by western blot data (<xref ref-type="fig" rid="fig2">Figure 2I</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>TAK1 phosphorylates PLCE1 at serine 1060.</title><p>(<bold>A</bold>) Tandem mass spectrometry showing serine 1060 (S1060) in PLCE1 was phosphorylated by TAK1. ECA-109 cells were transfected with a plasmid expressing <italic>Map3k7</italic>. 24 hr post-transfection, cells were harvested and subjected to co-immunoprecipitation. The resulting immunocomplex was analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). (<bold>B</bold>) TAK1 fails to phosphorylate PLCE1<sup>S1060A</sup>. ECA-109 cells were co-transfected with the plasmids carrying wildtype (WT) <italic>Plce1</italic>, mutated <italic>Plce1</italic> (PLCE1<sup>S1060A</sup>), or <italic>Map3k7</italic> as indicated. 24 hr post-transfection, cells were collected for western blot analysis. (<bold>C–E</bold>) Inhibition of TAK1 reduces PLCE1 phosphorylation at S1060. ECA-109 cells were co-transfected with the plasmids expressing <italic>Plce1</italic> or <italic>Map3k7</italic>. 6 hr post-transfection, TAK1 inhibitor (5Z)-7-oxozeaenol (Oxo; 10 µM) (<bold>C</bold>), or 10 µM Takinib (<bold>D</bold>), or 10 µM NG25 (<bold>E</bold>) was added in culture medium, and cells were cultured for additional 18 hr. Cells were then subjected to western blot analysis. Actin was used as a loading control. (<bold>F–G</bold>) Immunohistochemical analysis of TAK1 (<bold>F</bold>) and p-PLCE1 (<bold>G</bold>) expression in normal and esophageal squamous tumor tissues. n=4 biologically independent replicates. Scale bar = 20 µm. (<bold>H</bold>) Correlation between p-PLCE1 and TAK1 based on immunohistochemical data as shown in (<bold>F–G</bold>). 10 views for each sample were randomly chosen for Pearson’s correlation test. (<bold>I</bold>) TAK1 and p-PLCE1 protein levels in clinical samples. Protein levels were analyzed by western blot, and Actin was used as a loading control. n=4 biologically independent replicates. N: normal tissue; T: tumor tissue.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>TAK1 phosphorylates PLCE1 at serine 1060.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig2">Figure 2B, C, D, E, and I</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2">Figure 2B, C, D, E, and I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig2-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>TAK1 phosphorylates PLCE1 at serine 1060.</title><p>(<bold>A</bold>) TAK1 overexpression induces endogenous PLCE1 phosphorylation at serine 1060 (p-PLCE1 S1060). ECA-109 cells were transfected with a plasmid expressing TAK1. 24 hr post-transfection, cells were harvested and subjected to western blot analysis. Actin was used as a loading control. (<bold>B</bold>) TAK1 knockdown reduces endogenous p-PLCE1 S1060. ECA-109 cells were transfected with <italic>Map3k7</italic> siRNA. 48 hr post-transfection, cells were collected for analyzing p-PLCE1 S1060. Actin was used as a loading control. (<bold>C</bold>) TAK1 phosphorylates PLCE1 at S1060 in an in vitro kinase assay. ECA-109 cells were transfected with a plasmid carrying S protein tagged TAK1 (SP-TAK1), Myc tagged PLCE1 (Myc-PLCE1), or Myc tagged PLCE1 S1060A (Myc-PLCE1 S1060A). 24 hr post-transfection, cells were harvested and subjected to protein pull-down, the resulting purified SP-TAK1, Myc-PLCE1, and Myc-PLCE1 S1060A were incubated in a kinase assay buffer. The reaction mixtures were then resolved by SDS-PAGE, the resulting gels were analyzed by Coomassie blue staining or western blot. Lane M: marker; Lane 1: SP-TAK1+Myc-PLCE1; Lane 2: SP-TAK1+Myc-PLCE1 S1060A. The observed band for p-PLCE1 in lane 2 is likely due to the presence of endogenous wildtype PLCE1 in the TAK1 pull-down samples.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A, B, and C</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A, B, and C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>TAK1 phosphorylates PLCE1 to inhibit cell migration and invasion in ESCC</title><p>It has been well documented that PLCE1 plays a key role in cancer progression (<xref ref-type="bibr" rid="bib1">Abnet et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Gu et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Wang et al., 2010</xref>). Therefore, we predicted that the negative effects of TAK1 on ESCC migration and invasion may rely on PLCE1. To verify this hypothesis, we first examined whether PLCE1 affects cell migration and invasion. In ECA-109 cells, PLCE1 overexpression significantly increased the migration and invasion (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>). In accordance with these changes, the epithelial marker E-cadherin was repressed by PLCE1, whereas the mesenchymal markers including Vimentin, Snail, Slug, and ZEB-1 were activated (<xref ref-type="fig" rid="fig3">Figure 3D</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). The qRT-PCR data also revealed that Cdh1 was downregulated by PLCE1, while Vim, Snail1, and Snail2 were upregulated (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). To confirm these findings, we knocked down PLCE1 using siRNA. As shown in <xref ref-type="fig" rid="fig3">Figure 3E</xref>, Plce1 expression was markedly reduced by all three tested siRNAs. Similar changes were observed in the western blot data (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Among these siRNAs, siRNA-2# was found to exhibit the highest knockdown efficiency and was selected for subsequent experiments. On the contrary, as compared to PLCE1 overexpression, PLCE1 knockdown impeded cell migration and invasion (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A and B</xref>). The expression patterns of genes involved in EMT were contrary to those of PLCE1 overexpression (<xref ref-type="fig" rid="fig3">Figure 3I</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>). Moreover, similar to PLCE1 overexpression, the activation of PLCE1 by m-3M3FBS potentiated cell migration and invasion (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). PLCE1 inhibition by U-73122 recapitulated the phenotypes induced by PLCE1 knockdown (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>)<italic>.</italic></p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>PLCE1 positively regulates esophageal squamous cell carcinoma (ESCC) migration and invasion.</title><p>(<bold>A</bold>) Increased expression of PLCE1 in ECA-109 cells transfected with a plasmid expressing <italic>Plce1</italic>. (<bold>B–C</bold>) Increased expression of PLCE1 enhances cell migration and invasion. ECA-109 cells were transfected with the plasmid carrying <italic>Plce1</italic>. 24 hr post-transfection, cells were subjected to transwell (<bold>B</bold>) or wound healing (<bold>C</bold>) assay. n=5 biologically independent replicates. (<bold>D</bold>) Increased expression of PLCE1 in ECA-109 cells induces mesenchymal protein marker expression, while reduces epithelial protein marker expression. (<bold>E–F</bold>) Knockdown of PLCE1. ECA-109 cells were transfected with siRNAs targeting <italic>Plce1</italic>. 72 hr post-transfection, cells were harvested for analyzing PLCE1 expression by quantitative real time-PCR (qRT-PCR) (<bold>E</bold>) and western blot (<bold>F</bold>). (<bold>G–H</bold>) Reduced expression of PLCE1 inhibits cell migration and invasion. ECA-109 cells were transfected with <italic>Plce1</italic> siRNA-2. 48 hr post-transfection, cells were subjected to transwell (<bold>G</bold>) or wound healing (<bold>H</bold>) assay. n=3–5 biologically independent replicates. (<bold>I</bold>) Knockdown of PLCE1 promotes epithelial protein marker expression, while represses mesenchymal protein marker expression. ECA-109 cells were transfected with <italic>Plce1</italic> siRNA-2. 72 hr post-transfection, cells were harvested and subjected to western blot analysis. Protein level was detected by western blot, and Actin was used as a loading control. Gene expression was analyzed by qRT-PCR, and <italic>Gapdh</italic> was used as a house-keeping gene. Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. <italic>*</italic>p<italic>&lt;</italic>0.05, <italic>**</italic>p<italic>&lt;</italic>0.01, and <italic>***</italic>p<italic>&lt;</italic>0.001<italic>.</italic></p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>PLCE1 positively regulates esophageal squamous cell carcinoma (ESCC) migration and invasion.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig3">Figure 3A, D, F, and I</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig3">Figure 3A, D, F, and I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig3-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>PLCE1 promotes cell migration and invasion in ECA-109 cells.</title><p>(<bold>A–B</bold>) PLCE1 enhances cell migration and invasion in ECA-109 cells (A, transwell assay, scale bar = 500 µm; B, wound healing assay, scale bar = 100 µm). (<bold>C</bold>) Quantitative analysis of the western blot data as shown in <xref ref-type="fig" rid="fig3">Figure 3D</xref>. (<bold>D</bold>) PLCE1 increased expression of endogenous mesenchymal markers in ECA-109 cells, while decreased the expression of epithelial markers. Gene expression was analyzed by quantitative real time-PCR (qRT-PCR). <italic>Gapdh</italic> was used as a house-keeping gene. EV: empty vector. Data are presented as mean ± SD (error bars). Statistical significance was tested by unpaired Student’s t-test. n=3 biologically independent replicates. *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001 vs EV<italic>.</italic></p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>PLCE1 promotes cell migration and invasion in ECA-109 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>PLCE1 silencing inhibits cell migration and invasion in ECA-109 cells.</title><p>(<bold>A–B</bold>) Reduced expression of PLCE1 inhibits cell migration and invasion in ECA-109 cells. Cell migration and invasion were analyzed by transwell (<bold>A</bold>) or wound healing assay (<bold>B</bold>). Scale bar = 50 µm (<bold>A</bold>) or 100 µm (<bold>B</bold>). (<bold>C</bold>) The quantified data of western blots as shown in <xref ref-type="fig" rid="fig3">Figure 3I</xref>. (<bold>D</bold>) Reduced expression of PLCE1 decreased endogenous mesenchymal marker gene expression in ECA-109 cells, while increased epithelial marker gene expression. Gene expression was assayed by quantitative real time-PCR (qRT-PCR), and <italic>Gapdh</italic> was used as a house-keeping gene. NC: negative control<italic>.</italic> Data are presented as mean ± SD (error bars). n=3 biologically independent replicates. Statistical significance was tested by unpaired Student’s t-test. <italic>*</italic>p<italic>&lt;</italic>0.05, <italic>**</italic>p&lt;0.01, and <italic>***</italic>p&lt;0.001 vs NC.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>PLCE1 silencing inhibits cell migration and invasion in ECA-109 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig3-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Activation of PLCE1 stimulates cell migration and invasion in ECA-109 cells.</title><p>Cells were treated with 1 µM of m-3M3FBS for 24 hr. (<bold>A–D</bold>) Activation of PLCE1 by m-3M3FBS promotes cell migration and invasion (A–B, transwell assay, scale bar = 50 µm, n=5 biologically independent replicates; C–D, wound healing assay, scale bar = 100 µm, n=3 biologically independent replicates). Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. <italic>***</italic>p&lt;0.001.</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3—figure supplement 3—source data 1.</label><caption><title>Activation of PLCE1 stimulates cell migration and invasion in ECA-109 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig3-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Inhibition of PLCE1 reduces cell migration and invasion in ECA-109 cells.</title><p>Cells were treated with 10 µM of U-73122 for 24 hr. (<bold>A–D</bold>) Inhibition of PLCE1 attenuates cell migration and invasion in ECA-109 cells (A–B, transwell assay, scale bar = 500 µm; C–D, wound healing assay, scale bar = 100 µm). n=3 biologically independent replicates. Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. <italic>***</italic>p&lt;0.001 vs DMSO.</p><p><supplementary-material id="fig3s4sdata1"><label>Figure 3—figure supplement 4—source data 1.</label><caption><title>Inhibition of PLCE1 reduces cell migration and invasion in ECA-109 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig3-figsupp4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig3-figsupp4-v1.tif"/></fig></fig-group><p>Since PLCE1 is a lipid hydrolase, we next investigated whether TAK1-induced phosphorylation of PLCE1 affects its enzymatic activity. To this end, we transfected ECA-109 cells with a plasmid bearing Myc-PLCE1 or TAK1, and PLCE1 was captured by pull-down using anti-Myc beads, which was then subjected to enzyme activity assay. As shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, the PLCE1 activity was reduced in the presence of TAK1; however, the PLCE1 S1060A activity was not affected (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), indicating TAK1-induced phosphorylation at S1060 repressed PLCE1 activity. As a lipid hydrolase, PLCE1 catalyzes PIP2 hydrolysis to produce IP3 and DAG, both of which are secondary messengers involved in diverse cellular processes (<xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>). Therefore, we examined these two products to verify the inhibitory effect of TAK1 on PLCE1 expression. Our data showed that the productions of IP3 and DAG were increased by PLCE1, which was largely counteracted by TAK1 (<xref ref-type="fig" rid="fig4">Figure 4C and E</xref>). As a messenger, IP3 induces the endoplasmic reticulum to release Ca<sup>2+</sup> into the cytoplasm (<xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>). Hence, we analyzed cytoplasmic Ca<sup>2+</sup> levels using Fluo-4 AM staining. As expected, the signals for the cytoplasmic Ca<sup>2+</sup> were increased by PLCE1 in ECA-109 cells, and this trend was attenuated by TAK1 (<xref ref-type="fig" rid="fig4">Figure 4F and G</xref>). We also directly detected cytoplasmic Ca<sup>2+</sup> using a fluorospectrophotometer and observed similar changes (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Flow cytometry analysis also evidenced the increase in the cytoplasmic Ca<sup>2+</sup> induced by PLCE1 was prevented by TAK1 (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). This evidence indicates that TAK1 inhibits PLCE1 activity, which is likely due to TAK1-induced phosphorylation of PLCE1 at S1060. In order to further verify this hypothesis, a series of functional experiments was performed. For instance, we observed that TAK1 reversed PLCE1-induced cell migration and invasion; however, TAK1 failed to affect PLCE1 S1060A-induced cell migration and invasion (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). In addition to PLCE1, some other signaling pathways were also activated by TAK1. For example, TAK1 overexpression induced increases in p-IKK, p-JNK, p-p38 MAPK, and p-ERK in ECA-109 cells, whereas TAK1 knockdown reduced these protein levels (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). At this regard, PLCE1 is likely a unique substrate of TAK1 for transducing its inhibitory effects on ESCC migration and invasion, although some other signaling pathways are also affected by TAK1. Overall, these data clearly indicate that PLCE1 positively regulates ESCC migration and invasion. By inducing phosphorylation at S1060, TAK1 inhibits PLCE1 enzyme activity, thereby counteracting PLCE1-induced ESCC migration and invasion. PLCE1 is a downstream target of TAK1 that inhibits ESCC migration and invasion.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>TAK1 inhibits PLCE1 enzyme activity.</title><p>(<bold>A–B</bold>) Effects of TAK1 on PLCE1 (<bold>A</bold>) and PLCE1 S1060A (<bold>B</bold>) enzyme activity. ECA-109 cells were co-transfected with the plasmids expressing <italic>Plce1-Myc</italic> or <italic>Map3k7</italic>. 24 hr post-transfection, cells were subjected to pull-down assay by using the beads with anti-Myc antibody. PLCE1 enzyme activity was assayed by Phospholipases C (PLC) Activity Assay Kit. n=3 biologically independent replicates. (<bold>C–E</bold>) TAK1 abolishes PLCE1-induced inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) in ECA-109 (<bold>C</bold>), KYSE-150 (<bold>D</bold>), and TE-1 cells (<bold>E</bold>). Cells were transfected with the plasmids bearing <italic>Plce1</italic> or <italic>Map3k7</italic> as indicated. 24 hr post-transfection, cells were harvested for measuring IP3 and DAG. n=3 biologically independent replicates. (<bold>F</bold>) TAK1 attenuates PLCE1-induced intracellular Ca<sup>2+</sup> ([Ca<sup>2+</sup>]). ECA-109 cells were transfected with the plasmids bearing <italic>Plce1</italic> or <italic>Map3k7</italic> as indicated. [Ca<sup>2+</sup>] was labeled with Fluo-4 AM, which was then detected by a fluorescent microscope. Scale bar = 20 µm. (<bold>G</bold>) Quantified fluorescence intensity of [Ca<sup>2+</sup>] in ECA-109 cells. n=3 biologically independent replicates. (<bold>H</bold>) Fluorescence intensity of Fluo-4 in ECA-109, KYSE-150, and TE-1 cells was examined with a fluorospectrophotometer. n=3 biologically independent replicates. (<bold>I</bold>) Flow cytometry analysis of [Ca<sup>2+</sup>]. Cell treatments were described in (<bold>F</bold>). Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test (<bold>A–B</bold>) or two-tailed one-way ANOVA test (<bold>C–E, G–I</bold>). <italic>*</italic>p<italic>&lt;</italic>0.05, <italic>**</italic>p<italic>&lt;</italic>0.01, and <italic>***</italic>p&lt;0.001<italic>.</italic></p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>TAK1 inhibits PLCE1 enzyme activity.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>The negative impact of TAK1 on PLCE1-induced cell migration and invasion requires TAK1 kinase activity.</title><p>ECA-109 cells were transfected with plasmids expressing <italic>Plce1</italic>, mutated <italic>Plce1</italic> (S1060A), or <italic>Map3k7</italic> as indicated. 36 hr post-transfection, cell migration and invasion were assayed by transwell assay (<bold>A–B</bold>) and wound healing assay (<bold>C–D</bold>). n=5 biologically independent replicates. Scale bar = 500 µm (<bold>A</bold>); scale bar = 100 µm (<bold>C</bold>). Data are presented as mean ± SD. Statistical significance was tested by two-tailed one-way ANOVA test. <italic>***</italic>p&lt;0.001.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>The negative impact of TAK1 on PLCE1-induced cell migration and invasion requires TAK1 kinase activity.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Effects of TAK1 on p-IKK, p-JNK, p-ERK, and p-P38 MAPK in ECA-109 cells.</title><p>(<bold>A</bold>) TAK1 overexpression activates p-IKK, p-JNK, p-ERK, p-P38 MAPK. ECA-109 cells were transfected with a plasmid expressing TAK1. 24 hr post-transfection, cells were collected for western blot analysis. (<bold>B</bold>) Quantification data for the blots in (<bold>A</bold>). (<bold>C</bold>) TAK1 knockdown represses p-IKK, p-JNK, p-ERK, p-P38 MAPK. ECA-109 cells were transfected with <italic>Map3k7</italic> siRNA. 48 hr post-transfection, cells were harvested for western blot analysis. (<bold>D</bold>) Quantification data for the blots in (<bold>C</bold>). EV: empty vector; NC: negative control. Actin was used a loading control. *p<italic>&lt;</italic>0.05, **p<italic>&lt;</italic>0.01, and ***p<italic>&lt;</italic>0.001, by unpaired Student’s t-test.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Effects of TAK1 on p-IKK, p-JNK, p-ERK, and p-P38 MAPK in ECA-109 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata2"><label>Figure 4—figure supplement 2—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A and C</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata3"><label>Figure 4—figure supplement 2—source data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A and C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig4-figsupp2-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig4-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>TAK1 inhibits PLCE1-induced signal transduction in the PKC/GSK-3β/β-Catenin axis</title><p>PLCE1 hydrolyzes PIP2 to produce two important secondary messengers, DAG and IP3, which trigger Ca<sup>2+</sup> release from the endoplasmic reticulum into the cytoplasm to activate PKC (<xref ref-type="bibr" rid="bib20">Harden et al., 2009</xref>; <xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>), suggesting that PKC activation is responsible for PLCE1-induced cell migration and invasion in ESCC. In order to test this hypothesis, we treated cells with 2-APB, an IP3 receptor (IP3R) inhibitor, and found that 2-APB treatment almost completely reversed PLCE1-induced the intracellular Ca<sup>2+</sup> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Accordingly, PLCE1-induced cell migration and invasion were replenished by 2-APB in ECA-109 cells (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A–D</xref>). The changes in EMT gene expression induced by PLCE1 were largely reversed by 2-APB treatment (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2E</xref>). Similar to ECA-109 cells, 2-APB induced phenotypes in KYSE-150 and TE-1 cells (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>; <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>). BAPTA-AM, an intracellular Ca<sup>2+</sup> chelator, dampened PLCE1-induced cell migration and invasion in ECA-109 cells (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5</xref>). PKC is a promising downstream target of intracellular Ca<sup>2+</sup> (<xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>). Therefore, we investigated whether the PLCE1-induced cell growth was dependent on PKC activation. To this end, midostaurin was used to inhibit PKC, and our data showed that midostaurin almost completely abolished cell migration and invasion induced by PLCE1 (<xref ref-type="fig" rid="fig5s6">Figure 5—figure supplement 6</xref>).</p><p>It has been shown that PKC positively regulates the expression and stability of β-Catenin in a GSK-3β-dependent manner (<xref ref-type="bibr" rid="bib10">Duong et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Gwak et al., 2006</xref>; <xref ref-type="bibr" rid="bib30">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Ryu and Han, 2015</xref>; <xref ref-type="bibr" rid="bib48">Tejeda-Muñoz et al., 2015</xref>). Of note, β-Catenin is considered as a positive regulator in the EMT process (<xref ref-type="bibr" rid="bib50">Valenta et al., 2012</xref>). Therefore, we predicted that PLCE1 stimulates cell migration and invasion via the axis of PKC/GSK-3β/β-Catenin. To test this prediction, ECA-109 cells were treated with an IP3R inhibitor (2-APB), Ca<sup>2+</sup> chelator (BAPTA-AM), or PKC inhibitor (midostaurin), all of which successfully inhibited PKC activity, as evidenced by reduced phosphorylated PKC (p-PKC) (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>; <xref ref-type="fig" rid="fig5s7">Figure 5—figure supplement 7A–C</xref>). As a result, phosphorylated GSK-3b(p-GSK3b) was decreased by 2-APB, BAPTA-AM, and Midostaurin (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>; <xref ref-type="fig" rid="fig5s7">Figure 5—figure supplement 7A–C</xref>), indicating GSK-3β kinase activity was upregulated. Accordingly, phosphorylated β-Catenin (p-β-Catenin) was increased, leading to degradation of β-Catenin (<xref ref-type="fig" rid="fig5">Figure 5A-C</xref>; <xref ref-type="fig" rid="fig5s7">Figure 5—figure supplement 7A–C</xref>). As a downstream target of β-Catenin, MMP2 expression was inhibited by all three tested chemicals (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>; <xref ref-type="fig" rid="fig5s7">Figure 5—figure supplement 7A–C</xref>). The immunofluorescence data also showed that PLCE1-induced β-Catenin expression could be counteracted by 2-APB, BAPTA-AM, and Midostaurin (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). These results clearly indicate that PLCE1-induced cell migration and invasion in ESCC are likely via the axis of PKC/GSK-3β/β-Catenin. Furthermore, we observed that PLCE1-induced signal transduction in the axis of PKC/GSK-3β/β-Catenin could be inhibited by TAK1 (<xref ref-type="fig" rid="fig5">Figure 5E</xref>; <xref ref-type="fig" rid="fig5s7">Figure 5—figure supplement 7D</xref>). The expression of β-Catenin induced by PLCE1 was largely reversed by TAK1 (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). However, inactive TAK1 (TAK1 K63W) showed no such effect (<xref ref-type="fig" rid="fig5">Figure 5G</xref>; <xref ref-type="fig" rid="fig5s7">Figure 5—figure supplement 7E</xref>). Moreover, TAK1 failed to affect the PLCE1 S1060A induced signal cascade in the PKC/GSK-3β/β-Catenin axis (<xref ref-type="fig" rid="fig5">Figure 5H</xref>; <xref ref-type="fig" rid="fig5s7">Figure 5—figure supplement 7F</xref>). This further indicates that TAK1 phosphorylates PLCE1 at S1060 to inhibit its activity and downstream signal transduction in the PKC/GSK-3β/β-Catenin axis.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>TAK1 inhibits PLCE1-induced signal transduction in the axis of PKC/GSK-3β/β-Catenin.</title><p>(<bold>A</bold>) IP3R blocking inhibits PLCE1-induced signal transduction in the axis of PKC/GSK-3β/β-Catenin. ECA-109 cells were transfected with the plasmid expressing <italic>Plce1</italic> for 6 hr and then treated with 2-APB (10 µM) for additional 18 hr. (<bold>B</bold>) [Ca<sup>2+</sup>] blocking represses signal transduction in the axis of PKC/GSK-3β/β-Catenin induced by PLCE1. ECA-109 cells were transfected with the plasmid expressing <italic>Plce1</italic> for 6 hr and then treated with BAPTA-AM (10 µM) for additional 18 hr. (<bold>C</bold>) PKC inhibition blocks PLCE1 stimulated signal transduction in the axis of PKC/GSK-3β/β-Catenin. ECA-109 cells were transfected with the plasmid expressing <italic>Plce1</italic>. 6 hr post-transfection, cells were treated with 100 nM of Midostaurin for additional 18 hr. (<bold>D</bold>) PKC inhibition represses PLCE1-induced nuclear translocation of β-Catenin in ECA-109 cells. Cells were transfected with the plasmid expressing PLCE1. 6 hr post-transfection, 2-APB (10 µM), BAPTA-AM (10 µM), or Midostaurin (100 nM) was added in culture medium, and cells were cultured for additional 18 hr. Scale bar = 10 µm. Immunofluorescence was used to examine subcellular distribution of β-Catenin. (<bold>E</bold>) TAK1 counteracts PLCE1-induced signal transduction in the axis of PKC/GSK-3β/β-Catenin. ECA-109 cells were transfected with the plasmids expressing <italic>Plce1</italic> or <italic>Map3k7</italic> as indicated for 24 hr. (<bold>F</bold>) TAK1 reduces PLCE1-induced nuclear distribution of β-Catenin in ECA-109 cells. Cells were transfected with the plasmids expressing <italic>Plce1</italic> or <italic>Map3k7</italic> as indicated. Scale bar = 10 µm. (<bold>G</bold>) Dominant negative TAK1 (K63W) fails to block signal transduction in the axis of PKC/GSK-3β/β-Catenin/MMP2 induced by PLCE1. ECA-109 cells were transfected with the plasmids expressing <italic>Plce1</italic> or mutated <italic>Map3k7</italic> (TAK1 K63W) for 24 hr. (<bold>H</bold>) TAK1 has no effect on PLCE1 S1060A-induced signal transduction in the axis of PKC/GSK-3β/β-Catenin. ECA-109 cells were transfected with the plasmids expressing PLCE1 S1060A or TAK1 for 24 hr. Protein levels were analyzed by western blot, and Actin was used as a loading control. Representative blots were shown.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig5">Figure 5A, B, C, E, G, and H</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig5">Figure 5A, B, C, E,G, and H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>IP3R blockade inhibits PLCE1-induced intracellular calcium accumulation.</title><p>ECA-109 and KYSE-150 cells were transfected with a plasmid expressing <italic>Plce1</italic> for 6 hr and then treated with 2-APB (10 µM) for additional 18 hr. The intracellular calcium [Ca<sup>2+</sup>] was labeled with Fluo-4 AM. (<bold>A</bold>) Fluorescent imaging of the [Ca<sup>2+</sup>] in ECA-109 cells. Scale bar = 20 µm. (<bold>B</bold>) Quantitative analysis of Fluo-4 AM fluorescence intensity as shown in (<bold>A</bold>). (<bold>C</bold>) Fluorescence intensity of Fluo-4 in ECA-109 cells was examined under an absorbance photometer. n=3 biologically independent replicates. (<bold>D</bold>) Fluorescent imaging of the [Ca<sup>2+</sup>] in KYSE-150 cells. Scale bar = 20 µm. (<bold>E</bold>) Quantitative analysis of Fluo-4 AM fluorescence intensity in KYSE-150 cells as shown in (<bold>D</bold>). Data are presented as mean ± SD. Statistical significance was tested by two-tailed one-way ANOVA test. <italic>*</italic>p<italic>&lt;</italic>0.05 and <italic>**</italic>p&lt;0.01<italic>.</italic></p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>IP3R blockade inhibits PLCE1-induced intracellular calcium accumulation.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>2-APB treatment counteracts PLCE1-induced cell migration.</title><p>(<bold>A–D</bold>) IP3R blocking inhibits PLCE1 promoted cell migration and invasion. ECA-109 cells were transfected with the plasmid expressing <italic>Plce1</italic> for 6 hr and then cells were treated with 2-APB (10 µM) for additional 18 hr. Cell migration and invasion were analyzed by transwell (<bold>A, B</bold>) or wound healing (<bold>C, D</bold>) assay. n=5 biologically independent replicates. Scale bar = 500 µm (<bold>A</bold>) and 100 µm (<bold>C</bold>). (E) IP3R blocking counteracts PLCE1-induced changes in epithelial-mesenchymal transition (EMT) gene expression. The levels of mRNA were analyzed by quantitative real time-PCR (qRT-PCR), and <italic>Gapdh</italic> was used as a house-keeping gene. n=3 biologically independent replicates. Data are presented as mean ± SD. Statistical significance was tested by two-tailed one-way ANOVA test. <italic>*</italic>p&lt;0.05, **p&lt;0.01<italic>,</italic> and <italic>***</italic>p<italic>&lt;</italic>0.001.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>2-APB treatment counteracts PLCE1-induced cell migration.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig5-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>IP3R inhibition represses PLCE1-stimulated cell migration and invasion in KYSE-150 cells<italic>.</italic></title><p>Cells were transfected with plasmid expressing <italic>Plce1</italic> for 6 hr and then treated with 2-APB (10 µM) for additional 18 hr. (<bold>A–B</bold>) Transwell assay showing the application of 2-APB attenuates cell migration and invasion induced by PLCE1. Scale bar = 500 µm. n=5 biologically independent replicates. (<bold>C–D</bold>) Wound healing assay showing the treatment of 2-APB represses cell migration induced by PLCE1. Scale bar = 100 µm. n=5 biologically independent replicates. (<bold>E</bold>) 2-APB counteracts PLCE1-induced changes in epithelial-mesenchymal transition (EMT) gene expression. The mRNA levels were detected by quantitative real time-PCR (qRT-PCR), and <italic>Gapdh</italic> was used as a house-keeping gene. n=3 biologically independent replicates. Data are presented as mean ± SD. Statistical significance was tested by two-tailed one-way ANOVA test. <italic>*</italic>p<italic>&lt;</italic>0.05, <italic>**</italic>p&lt;0.01, and <italic>***</italic>p&lt;0.001.</p><p><supplementary-material id="fig5s3sdata1"><label>Figure 5—figure supplement 3—source data 1.</label><caption><title>IP3R inhibition represses PLCE1-stimulated cell migration and invasion in KYSE-150 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig5-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig5-figsupp3-v1.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>IP3R inhibition reduces PLCE1-stimulated cell migration and invasion in TE-1 cells<italic>.</italic></title><p>Cells were transfected with plasmid expressing <italic>Plce1</italic> for 6 hr and then treated with 2-APB (10 µM) for additional 18 hr. (<bold>A–D</bold>) Cell migration and invasion induced by PLCE1 were repressed by the application of 2-APB in TE-1 cells. Cell migration and invasion were analyzed by transwell assay (A–B, scale bar = 500 µm) and wound healing assay (C–D, scale bar = 100 µm). n=5 biologically independent replicates. (<bold>E</bold>) 2-APB abolishes PLCE1-induced changes in epithelial-mesenchymal transition (EMT) gene expression in TE-1 cells. Gene expression was analyzed by quantitative real time-PCR (qRT-PCR), and <italic>Gapdh</italic> was used as a house-keeping gene. n=3 biologically independent replicates. Data are presented as mean ± SD. Statistical significance was tested by two-tailed one-way ANOVA test. <italic>**</italic>p&lt;0.01 and <italic>***</italic>p&lt;0.001<italic><bold>.</bold></italic></p><p><supplementary-material id="fig5s4sdata1"><label>Figure 5—figure supplement 4—source data 1.</label><caption><title>IP3R inhibition reduces PLCE1-stimulated cell migration and invasion in TE-1 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig5-figsupp4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig5-figsupp4-v1.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 5.</label><caption><title>[Ca<sup>2+</sup>] blockade inhibits PLCE1-induced cell migration and invasion in ECA-109 cells.</title><p>(<bold>A</bold>–<bold>D</bold>) [Ca<sup>2+</sup>] blocking inhibits PLCE1 promoted cell migration and invasion. ECA-109 cells were transfected with the plasmid expressing <italic>Plce1</italic> for 6 hr and then treated with BAPTA-AM (10 µM) for additional 18 hr. Cell migration and invasion were tested by transwell (<bold>A, B</bold>) or wound healing (<bold>C, D</bold>) assay. n=5 biologically independent replicates. Scale bar = 500 µm (<bold>A</bold>) and 100 µm (<bold>C</bold>). Data are presented as mean ± SD. Statistical significance was tested by two-tailed one-way ANOVA test. <italic>**</italic>p&lt;0.01 and <italic>***</italic>p<italic>&lt;</italic>0.001<italic><bold>.</bold></italic></p><p><supplementary-material id="fig5s5sdata1"><label>Figure 5—figure supplement 5—source data 1.</label><caption><title>[Ca<sup>2+</sup>] blockade inhibits PLCE1-induced cell migration and invasion in ECA-109 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig5-figsupp5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig5-figsupp5-v1.tif"/></fig><fig id="fig5s6" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 6.</label><caption><title>PKC inhibition counteracts PLCE1-induced cell migration and invasion<italic>.</italic></title><p>(<bold>A</bold>–<bold>D</bold>) ECA-109 cells were transfected with the plasmid expressing <italic>Plce1</italic> for 6 hr and then treated with Midostaurin (100 nM) for additional 18 hr. Cell migration and invasion were tested by transwell (<bold>A, B</bold>) or wound healing (<bold>C, D</bold>) assay. n=5 biologically independent replicates. Scale bar = 500 µm (<bold>A</bold>) and 100 µm (<bold>C</bold>). Data are presented as mean ± SD. Statistical significance was tested by two-tailed one-way ANOVA test. <italic>*</italic>p&lt;0.05, <italic>**</italic>p&lt;0.01, and <italic>***</italic>p&lt;0.001<italic><bold>.</bold></italic></p><p><supplementary-material id="fig5s6sdata1"><label>Figure 5—figure supplement 6—source data 1.</label><caption><title>PKC inhibition counteracts PLCE1-induced cell migration and invasion.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig5-figsupp6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig5-figsupp6-v1.tif"/></fig><fig id="fig5s7" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 7.</label><caption><title>TAK1 mitigates PLCE1-induced signal transduction in the axis of PKC/GSK-3β/β-Catenin.</title><p>(<bold>A–F</bold>) Quantified data for the western blots as shown in <xref ref-type="fig" rid="fig5">Figure 5</xref>. n=3 biologically independent replicates. Data are presented as mean ± SD. Statistical significance was tested by two-tailed one-way ANOVA test. *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p><p><supplementary-material id="fig5s7sdata1"><label>Figure 5—figure supplement 7—source data 1.</label><caption><title>TAK1 mitigates PLCE1-induced signal transduction in the axis of PKC/GSK-3β/β-Catenin.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig5-figsupp7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig5-figsupp7-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>TAK1 inhibition promotes ESCC metastasis in vivo</title><p>To examine TAK1-regulated ESCC metastasis in vivo, a xenograft model with nude mice was used. Mice were injected with ECA-109 cells via the tail vein, and treated daily with Takinib (50 mg/kg) or corn oil (vehicle) for consecutive 15 days. Eight weeks later, the mice were sacrificed for analysis of cancer cell metastasis. We found that four of six mice in the Takinib group developed lung metastasis, while only one of six mice in the vehicle group developed lung metastasis. Moreover, the number of metastatic nodules in lung tissues was higher in Takinib-treated mice (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>). In addition, the effects of TAK1 inhibition on the axis of PKC/GSK-3β/β-Catenin was examined. As shown in <xref ref-type="fig" rid="fig6">Figure 6D</xref>, TAK1 inhibition by Takinib activated PKC, leading to increased p-GSK-3β levels. As a result, p-β-Catenin was reduced and MMP2 expression was upregulated (<xref ref-type="fig" rid="fig6">Figure 6D and E</xref>). Notably, the p-TAK1 levels were decreased by Takinib, indicating that TAK1 activity was successfully inhibited (<xref ref-type="fig" rid="fig6">Figure 6D and E</xref>). Accordingly, p-PLCE1 expression was decreased in Takinib-treated mice (<xref ref-type="fig" rid="fig6">Figure 6D and E</xref>). The body weight growth rate was not affected by Takinib (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). These data indicate that TAK1 represses ESCC metastasis in vivo, and this benefit is likely due to TAK1-mediated phosphorylation of PLCE1 at S1060.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Inhibition of TAK1 by Takinib promotes esophageal squamous cell carcinoma (ESCC) metastasis in nude mice.</title><p>Each mouse was intravenously injected with 1×10<sup>6</sup> ECA-109 cells diluted in 100 µl PBS. Mice were treated with Takinib at the dosage of 50 mg/kg/day for 15 days, mice in control group were received vehicle (corn oil). Eight weeks later, mice were sacrificed, and the lungs and livers from each group were collected and photographed. (<bold>A</bold>) Typical images of specimens. (<bold>B</bold>) Hematoxylin and eosin staining of metastatic nodules in lungs. (<bold>C</bold>) The number of nodules in lungs. (<bold>D</bold>) Takinib treatment induces signal transduction in the axis of PKC/GSK-3β/β-Catenin. Protein levels were analyzed by western blot, and Actin was used as a loading control. n=3 biologically independent replicates. (<bold>E</bold>) Quantitative analysis of the western blot data shown in (<bold>D</bold>). Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. <italic>*</italic>p<italic>&lt;</italic>0.05<italic>, **</italic>p&lt;0.01, and <italic>***</italic>p&lt;0.001<italic>.</italic></p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Inhibition of TAK1 by Takinib promotes esophageal squamous cell carcinoma (ESCC) metastasis in nude mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig6">Figure 6D</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6">Figure 6D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig6-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>The effects of Takinib on mouse body weight and knockdown of PLCE1 by lentivirus in ECA-109 cells.</title><p>(<bold>A</bold>) The body weight growth rate was not altered by Takinib. (<bold>B</bold>) The mRNA levels of <italic>Plce1</italic> were decreased by LV-shPLCE1. ECA-109 cells were transduced with LV-shPLCE1 for 48 hr, gene expression was analyzed by quantitative real time-PCR (qRT-PCR), and <italic>Gapdh</italic> was used as a house-keeping gene. n=4 biologically independent replicates. (<bold>C</bold>) The protein levels of PLCE1 were decreased by LV-shPLCE1. ECA-109 cells were transduced with LV-shPLCE1 for 48 hr, protein expression was analyzed by western blot, and Actin was used as a loading control. n=3 biologically independent replicates. <italic>***</italic>p<italic>&lt;</italic>0.001, unpaired Student’s t-test.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>The effects of Takinib on mouse body weight and knockdown of PLCE1 by lentivirus in ECA-109 cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig6-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata3"><label>Figure 6—figure supplement 1—source data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig6-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>PLCE1 facilitates ESCC metastasis in vivo</title><p>To further verify the function of PLCE1 in ESCC metastasis, we generated a stable cell line with PLCE1 knockdown using a lentivirus bearing PLCE1 shRNA (LV-shPLCE1) (SI Appendix, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B and C</xref>). Cells with low PLCE1 expression were injected into nude mice via the tail vein to generate a mouse xenograft tumor model. Eight weeks later, the mice were sacrificed, and the nodule number and incidence rate were reduced in mice injected with LV-shPLCE1 cells (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>). In addition, western blot analysis showed that PLCE1 silencing inhibited signal transduction in the PKC/GSK-3β/β-Catenin axis, as evidenced by reduced p-PKC and p-GSK-3β, and increased p-β-Catenin (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref>). Accordingly, MMP2 was decreased (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref>). These results further confirm that PLCE1 plays a key role in cancer cell metastasis in ESCC.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>PLCE1 knockdown inhibits esophageal squamous cell carcinoma (ESCC) metastasis in nude mice.</title><p>ECA-109 cells were transduced with lentivirus bearing PLCE1 shRNA (LV-shPLCE1) or NC shRNA (LV-shPLCE1 NC). Each mouse was intravenously injected with the LV transduced cells (1×10<sup>6</sup> cells/mouse). Eight weeks later, mice were sacrificed, and the lungs and livers from each group were collected and photographed. (<bold>A</bold>) Typical images of lung specimens. (<bold>B</bold>) Hematoxylin and eosin staining of metastatic nodules in lungs. (<bold>C</bold>) The number of nodules in lungs. (<bold>D</bold>) PLCE1 knockdown represses signal transduction in the axis of PKC/GSK-3β/β-Catenin. Protein levels were analyzed by western blot, and Actin was used as a loading control. n=3 biologically independent replicates. (<bold>E</bold>) Quantitative analysis of the western blot data shown in (<bold>D</bold>). Data are presented as mean ± SD. Statistical significance was tested by unpaired Student’s t-test. <italic>**</italic>p&lt;0.01 and <italic>***</italic>p&lt;0.001<italic>.</italic></p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>PLCE1 knockdown inhibits esophageal squamous cell carcinoma (ESCC) metastasis in nude mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-97373-fig7-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig7">Figure 7D</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig7-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig7">Figure 7D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-97373-fig7-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-97373-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>TAK1 is a serine/threonine kinase and a major member of the MAPK family (<xref ref-type="bibr" rid="bib62">Zhu et al., 2021</xref>). In response to various cytokines, pathogens, lipopolysaccharides, hypoxia, and DNA damage, the E3 ligases TRAF2 and TRAF6 activate TAK1 through Lys63-linked polyubiquitylation, and then TAK1 undergoes auto-phosphorylation at Ser192 and Thr184/187 to achieve full activation (<xref ref-type="bibr" rid="bib41">Skaug et al., 2009</xref>; <xref ref-type="bibr" rid="bib43">Sorrentino et al., 2008</xref>). Consequently, activated TAK1, in turn, phosphorylates downstream substrates in order to initiate the NF-kB and MAPKs (i.e. ERK, p38 MAPK, and JNK) signaling pathways, thereby participates in cellular inflammation, immune response, fibrosis, cell death, and cancer cell invasion and metastasis (<xref ref-type="bibr" rid="bib58">Yang et al., 2022</xref>; <xref ref-type="bibr" rid="bib61">Zhou et al., 2021</xref>). TAK1 has been shown to decrease in high-grade human prostate cancer, and TAK1 deficiency promotes prostate tumorigenesis by increasing androgen receptor (AR) protein levels and activity or by activating the p38 MAPK pathway (<xref ref-type="bibr" rid="bib23">Huang et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Wu et al., 2012</xref>). Similarly, hepatocyte-specific TAK1 ablation drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and HCC (<xref ref-type="bibr" rid="bib44">Su et al., 2023</xref>; <xref ref-type="bibr" rid="bib46">Tan et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Xia et al., 2021</xref>). Furthermore, TAK1 represses the transcription of human telomerase and activates the tumor suppressor protein LKB1, indicating that TAK1 is a tumor suppressor (<xref ref-type="bibr" rid="bib2">Adhikari et al., 2007</xref>; <xref ref-type="bibr" rid="bib13">Fujiki et al., 2007</xref>; <xref ref-type="bibr" rid="bib56">Xie et al., 2006</xref>). Consistent with these findings, in our previous study, we found that TAK1 expression was reduced in esophageal squamous tumors when compared to that in adjacent normal tissues, and that TAK1 was negatively correlated with esophageal squamous tumor patient survival (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). In this study, we extended our research on TAK1 and observed that TAK1 inhibits cell migration and invasion in ESCC. In contrast, TAK1 plays a positive role in tumor cell proliferation, migration, invasion, colony formation, and metastasis, especially in breast, pancreatic, and non-small-cell lung cancers (<xref ref-type="bibr" rid="bib25">Kim et al., 2023</xref>; <xref ref-type="bibr" rid="bib39">Santoro et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Tripathi et al., 2019</xref>). Therefore, TAK1 may play a pleiotropic role in various cancer cell types.</p><p>As a kinase, TAK1 is considered as a central regulator of tumor cell proliferation, migration, and invasion and has been demonstrated to play tumor suppression or activation role via the NF-κB and MAPK activation (<xref ref-type="bibr" rid="bib34">Mukhopadhyay and Lee, 2020</xref>; <xref ref-type="bibr" rid="bib53">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib60">Zhang et al., 2023</xref>). However, the precise molecular and cellular mechanisms through which TAK1 regulates ESCC metastasis remain unclear. As previously reported, using co-immunoprecipitation coupled with mass spectrometry (MS/MS), we identified RASSF9 as a downstream target of TAK1 to repress on cell proliferation in ESCC (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). By phosphorylating RASSF9 at S284, TAK1 negatively regulates ESCC proliferation (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). We also found that PLCE1 was present in the immunocomplex and was phosphorylated at S1060 in the presence of TAK1 in ECA-109 cells. It should be mentioned that, TAK1 inhibitors cannot completely abolish p-PLCE1 S1060 in cells and mice, which might be due to some other kinases also targeting PLCE1 at S1060. As a member of the human phosphoinositide-specific PLC family, PLCE1 is activated by various intracellular and extracellular signaling molecules, including hormones, cytokines, neurotransmitters, and growth factors (<xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>). Numerous studies have shown that PLCE1 plays a key role in cancer development and progression via various pathways (<xref ref-type="bibr" rid="bib1">Abnet et al., 2010</xref>; <xref ref-type="bibr" rid="bib11">Fan et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Ghosh et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">He et al., 2016</xref>; <xref ref-type="bibr" rid="bib59">Yue et al., 2019</xref>). Moreover, PLCE1 has been identified as a susceptibility gene for ESCC (<xref ref-type="bibr" rid="bib1">Abnet et al., 2010</xref>; <xref ref-type="bibr" rid="bib51">Wang et al., 2010</xref>). This suggests that PLCE1 is a potential downstream target for transducing the negative effects of TAK1 on ESCC migration and invasion.</p><p>Once activated, PLCE1 catalyzes the hydrolysis of PIP2 on the cell membrane in order to produce two secondary messengers IP3 and DAG; IP3 induces Ca<sup>2+</sup> release from the ER into the cytoplasm via IP3R; both Ca<sup>2+</sup> and DAG are potent activators of PKC. PLCE1 regulates cell growth, proliferation, and differentiation, thereby playing a key role in tumor growth and development (<xref ref-type="bibr" rid="bib4">Bunney and Katan, 2010</xref>; <xref ref-type="bibr" rid="bib24">Kadamur and Ross, 2013</xref>; <xref ref-type="bibr" rid="bib27">Land and Rubin, 2017</xref>; <xref ref-type="bibr" rid="bib42">Smrcka et al., 2012</xref>). Consistent with these observations, we observed that PLCE1-overexpressing cells exhibited a higher production of intracellular IP3, DAG, and intracellular Ca<sup>2+</sup>. We found that PLCE1 overexpression accelerated cell migration and invasion, while PLCE1 knockdown resulted in the opposite phenotype. Moreover, in the presence of TAK1, PLCE1-induced cell migration and invasion were largely counteracted. Considering that TAK1 is a protein kinase, we propose that TAK1 phosphorylates PLCE1 at S1060 to inhibit its enzymatic activity, thus impedes cell migration and invasion in ESCC. Indeed, PLCE1 activity was blunted in the presence of TAK1, whereas the mutated PLCE1 (PLCE1 S1060A) was not affected. It has been shown that PKC positively regulates the expression and stability of β-Catenin in a GSK-3β-dependent manner (<xref ref-type="bibr" rid="bib10">Duong et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">Gwak et al., 2006</xref>; <xref ref-type="bibr" rid="bib37">Ryu and Han, 2015</xref>). Therefore, we investigated the impact of PLCE1 on the PKC/GSK-3β/β-Catenin axis. As expected, our data revealed that PLCE1 promotes cell migration and invasion in ESCC by activating the PKC/GSK-3β/β-Catenin pathway, results in a series of phosphorylation modification in PKC and GSK-3β. As a result, phosphorylated β-Catenin decreased, leading to a higher stability of β-Catenin, which eventually promotes the EMT process by affecting epithelial and mesenchymal gene expression.</p><p>In summary, our findings have indicated TAK1 negatively regulates the cell migration and invasion of ESCC. Mechanistically, TAK1 phosphorylates PLCE1 at residue S1060 to inhibit phospholipase activity, leading to a reduction in IP3 and DAG. Consequently, PKC activity was blunted, which results in decreased phosphorylated GSK-3β and increased phosphorylated β-Catenin. As a consequence, the stability of β-Catenin was decreased and its transcriptional activity was blunted. Thus, epithelial marker gene expression was upregulated by TAK1, whereas the mesenchymal marker gene expression was downregulated. These outcomes eventually lead to a breakdown in the cell migration and invasion of ESCC. Hence, our data revealed a new facet of TAK1 in the EMT process in ESCC by inhibiting PLCE1 activity and its downstream signal transduction in the axis of PKC/GSK-3β/β-Catenin. Moreover, TAK1 and, together with its downstream target, PLCE1, are potential drug targets for the development of agents for treating ESCC.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Antibodies, inhibitors, and growth factors</title><p>The following antibodies were used: rabbit polyclonal anti-PLCE1 (#PA5-100856; Invitrogen, Carlsbad, CA, USA). Rabbit monoclonal antibodies against TAK1 (#5206), phospho-TAK1 (Ser412, #9339), PKCα (#2056), phospho-PKC (pan) (gamma Thr514) (#38938), GSK-3β (#9315), phospho-GSK-3β (Ser9) (#5558), β-Catenin (#8480), phospho-β-Catenin (Ser33/37/Thr41) (#9561), MMP-2 (#87809), mouse monoclonal antibodies against Actin (#3700), Myc-Tag (Sepharose Bead Conjugate) (#55464), Epithelial-Mesenchymal Transition (EMT) antibody sample kit (#9782), phosphor-IKK (#2078), IKK (#61294), phosphor-JNK (#4668), JNK (#9252), phospho-ERK (#4370), ERK (#9102), phospho-P38 MAPK (#9211), P38 MPAK (#9212), and normal rabbit IgG (#2729) were from Cell Signaling Technology (Beverley, MA, USA). TAK1 inhibitors 5Z-7-oxozeaenol (O9890), NG25 (SML1332), and Takinib (SML2216) (#662009) were purchased from Sigma-Aldrich (St. Louis, MO, USA). An intracellular calcium chelator BAPTA-AM (HY-100545), a PKC inhibitor Midostaurin (HY-10230), and an IP3R antagonist (HY-W009724) were obtained from MedChemExpress (NJ, USA). EGF Recombinant Human Protein (#PHG0311) was purchased from Gibco (Carlsbad, CA, USA).</p></sec><sec id="s4-2"><title>Cell culture</title><p>Human ESCC cell lines ECA-109, KYSE-150, and TE-1 were purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). HEK-293 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Hyclone, UT, USA) containing 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA), 100 U/ml penicillin, and 100 μg/ml streptomycin (Life Technologies, Carlsbad, CA, USA) at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>. All cultures were routinely screened for the absence of mycoplasma contamination using the ATCC Universal Mycoplasma Detection Kit (#30-1012K).</p></sec><sec id="s4-3"><title>Human esophageal squamous tumor specimens</title><p>This study utilized pathological specimens obtained from 10 patients with histologically confirmed invasive ESCC at the Affiliated Hospital of Nantong University. All specimens were collected after obtaining written informed consent from participants, in strict accordance with the ethical principles outlined in the Declaration of Helsinki. The cohort consisted of seven male and three female patients, aged 43–70 years. The research protocol received ethical approval from the Institutional Review Board of the Affiliated Hospital of Nantong University (Ethical Approval No.: 2015 L132).</p></sec><sec id="s4-4"><title>Generation of antibodies against phospho-PLCE1 (S1060)</title><p>A rabbit polyclonal antibody that recognizing phospho-PLCE1 (S1060) was raised against the c-WSARNPS(p)PGTSAK peptide at Absin (Shanghai, China). Briefly, the phosphorylated polypeptide c-WSARNPS(p)PGTSAK was synthesized as the target peptide. Two rabbits were then immunized with the target peptide antigen. The non-phosphorylated polypeptide c-WSARNPSPGTSAK was used as a control. The rabbits were sacrificed and blood was collected for further purification. The prepared antibody was verified and stored at –20°C until use.</p></sec><sec id="s4-5"><title>CRISPR-Cas9-mediated TAK1 deletion</title><p><italic>Map3k7</italic> was deleted using the CRISPR-Cas9 method described previously (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). Briefly, we designed an integrated vector based on OriP/EBNA1 (epiCRISPR) bearing gRNA, Cas9, and puromycin resistance genes. ECA-109 cells were transfected with plasmids using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s instructions. The cells were cultured in a medium containing 2.5 μg/ml puromycin for 1 week. Surviving stable cells were used for further experiments. The gRNA sequences are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-6"><title>Plasmid construction</title><p>The full-length coding regions of <italic>Map3k7</italic> was synthesized by Heyuan Biotechnology Company (Shanghai, China). The synthesized <italic>Map3k7</italic> was cloned into pcDNA3.1(+) (Invitrogen, Carlsbad, CA, USA) vector using EcoR I and Xho I. Correct construction was confirmed by DNA sequencing. The plasmid of pRK5-N-myc PLCE1 was a gift from Dr. Friedhelm Hildebrandt (<xref ref-type="bibr" rid="bib6">Chaib et al., 2008</xref>). PLCE1 (S1060A) was generated using a PCR-based mutagenesis kit (Stratagene, La Jolla, CA, USA) using pRK5-N-myc-human PLCE1 as template. The primer sequences are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. All plasmids were confirmed by sequencing. For transient transfection, the plasmids were transfected into ESCC cells with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions.</p><p><italic>Map3k7</italic> short interfering RNAs (siRNAs), <italic>Plce1</italic> siRNAs, and a corresponding scrambled siRNA were chemically synthesized at RiboBio (Guangzhou, China). The siRNA sequences are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The siRNAs were transfected into ECA-109 cells with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA), in accordance with the instructions.</p></sec><sec id="s4-7"><title>Lentivirus transduction</title><p>LV-<italic>Map3k7</italic> shRNA and LV-NC shRNA were produced at Hanbio (Shanghai, China). LV-<italic>Plce1</italic> shRNA (LV-shPLCE1) and LV-NC shRNA were produced at OBiO (Shanghai, China). Lentivirus transduction was performed as previously described (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). To generate a stale cell line with low PLCE1 expression, ECA-109 cells were transduced with LV-shPLCE1. 24 hr post-transduction, cells were treated with 2.5 μg/ml puromycin to eliminate non-transduced cells. The efficiency of lentivirus with knockdown of TAK1 or PLCE1 were verified by qRT-PCR and western blot analysis.</p></sec><sec id="s4-8"><title>Quantitative real time-PCR</title><p>Total RNA was isolated from the ESCC cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and quantified. Then, reversely transcribed into First strand cDNA using the PrimeScript RT reagent kit (Takara, Tokyo, Japan) according to the manufacturer’s instruction. qRT-PCR was used to analyze the expression level of target gene mRNA by using a Fast Start Master SYBR Green Kit (Roche) on the RocheLightCycler96 instrument and software (Roche, Basel, Switzerland). The qRT-PCR conditions were as follows: 95°C for 6 min, followed by 40 cycles of 95°C for 10 s, 60°C for 30 s, 72°C for 10 s. Primer sequences were shown in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Relative quantitation of target genes was normalized to that of GAPDH mRNA and were analyzed using the 2<sup>-△△CT</sup> method<italic>.</italic></p></sec><sec id="s4-9"><title>Protein extraction and western blot analysis</title><p>Western blotting was performed as previously described (<xref ref-type="bibr" rid="bib47">Tan et al., 2022</xref>). Briefly, total protein was extracted from the cells and tissues using protein lysis buffer supplemented with protease and phosphatase inhibitors (Roche Applied Science, Penzberg, Germany). Protein concentrations were assayed by the Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Subsequently, equal amounts of protein were separated with 6% or 10% SDS-PAGE, and then protein were transferred onto 0.45 μm PVDF membranes. After blocking with 5% BSA in TBST for 1 hr<italic>,</italic> membranes were incubated with primary antibodies at 4°C overnight<italic>.</italic> The membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hr at room temperature<italic>.</italic> Protein signals were visualized using an enhanced chemiluminescence (ECL) reagent (Thermo Fisher Scientific, Waltham, MA, USA) and quantitatively analyzed using ImageJ (NIH<italic>).</italic> Actin was used as a loading control<italic>.</italic></p></sec><sec id="s4-10"><title>Wound healing assay</title><p>For wound healing assay, ibidi Culture-Inserts (ibidi GmbH) were used to guarantee the uniformity of each initial (0 hr) wound. In brief, 3×10<sup>4</sup> cells were seeded into the ibidi Culture-Inserts (70 μl cell suspension for each side of the scratch chamber) and incubated in medium containing 10% FBS. After 24 hr, cells were grown to almost 100% confluence. Then, the scratch chambers were removed to make the wounds and rinsed with PBS for three times to remove the suspended cells. Cells were continually cultured in DMEM supplemented with 1% FBS and photographed randomly at 0 hr, 24 hr, and 48 hr, respectively. Wound closure was calculated using the ImageJ software according to the following formula: Wound healing rate (%) = (24 hr or 48 hr wound area - 0 hr wound area)/0 hr wound area × 100%.</p></sec><sec id="s4-11"><title>Transwell assay</title><p>Cell migration and invasion were determined using transwell assay. For migration assay, 5×10<sup>4</sup> cells in 200 μl of serum-free culture medium were placed into the upper chambers (8.0 μm pore size, Corning, NY, USA) in 24-well plates. For cell invasion assay, 5×10<sup>4</sup> cells in 200 μl of serum-free culture medium were placed into the upper chambers coated with 80 µl of Matrigel (BD Bioscience). The lower chamber was added with 500 μl of DMEM supplemented with 10% FBS. After incubating for 24 hr at 37°C, the non-migrating cells in the upper chamber were gently wiped with a cotton swab. The chambers were then fixed with 4% paraformaldehyde for 20 min and dyed with 0.1% crystal violet for 30 min. The migration and invasive cells onto the lower side of the chamber were imaged (randomly selected five fields) and counted under a light microscope (Olympus BX51, Tokyo, Japan) at ×200.</p></sec><sec id="s4-12"><title>Immunofluorescence</title><p>Cells were seeded into a 24-well plate with glass coverslips (2×10<sup>4</sup> per well). Next day, cells were transfected with plasmid expressing PLCE1 or TAK1 for 6 hr and then treated with BAPTA-AM (10 µM) or 2-APB (10 µM) or Midostaurin (100 nM) for additional 18 hr, respectively. For immunofluorescence staining, cells were fixed with methanol at room temperature for 15–20 min and washed three times in PBS, each time for 10 min. Then, cells were blocked with 5% BSA solution containing 0.1–0.5% Triton X-100 for 2 hr at room temperature. After blocking, cells were incubated with rabbit anti-β-Catenin antibody overnight at 4°C, followed by an Alexa Fluor 488/594-conjugated secondary antibody incubation for 2 hr at room temperature. Finally, the nuclei were stained with Hoechst. Photographs (×400) were taken with an Olympus fluorescence microscope (BX51, Tokyo, Japan).</p></sec><sec id="s4-13"><title>In vitro kinase assay</title><p>Protein pull-down was performed using a previously reported method (2). Briefly, ECA-109 cells were transfected with a plasmid expressing Myc tagged PLCE1 (Myc-PLCE1), Myc tagged PLCE1 S1060A (Myc-PLCE1 S1060A), or S protein tagged TAK1 (SP-TAK1). 24 hr post-transfection, cells were harvested for preparing total cell lysates, which was then subjected to protein pull-down using the Myc-Tag beads (Sepharose Bead Conjugate; #55464; CST, Beverley, MA, USA) or S-protein Agarose (#69704; Millipore, Billerica, MA, USA). After 4 hr incubation on a rotator, unbound proteins were removed using ice-cold wash buffer. Myc-PLCE1, Myc-PLCE1 S1060A, and SP-TAK1 were eluted and collected. The purified SP-TAK1 was incubated with Myc-PLCE1 or Myc-PLCE1 S1060A in a kinase assay buffer (Cell Signaling Technology, #9802), in which 200 µM ATP (Cell Signaling Technology, #9804) was added. The reaction was performed at 30°C for 30 min. The reaction was terminated by adding 5×loading buffer to each sample. After boiling at 100°C for 5 min, the samples were resolved by SDS-PAGE, the resulting gels were analyzed by Coomassie blue stating or western blot.</p></sec><sec id="s4-14"><title>Measurement of intracellular-free Ca<sup>2+</sup></title><p>Cells were transfected with plasmid expressing PLCE1 and/or TAK1 for 6 hr and then treated with BAPTA-AM (10 µM), 2-APB (10 µM), or Midostaurin (100 nM) for additional 18 hr, respectively. Intracellular Ca<sup>2+</sup> levels in the treated cells were measured using a Fluo-4 AM Assay Kit (Beyotime, Jiangsu, China). The cells were then washed with PBS and incubated with 1 μM Fluo-4 AM in PBS at 37°C for 30 min. The cells were then washed with PBS three times and further incubated for 20 min to ensure that Fluo-4 AM was completely transformed into Fluo-4. Finally, Fluo-4 fluorescence intensity was detected using a confocal laser scanning fluorescence microscope (Olympus BX51, Tokyo, Japan), a fluorescence microplate (BioTek Instruments, Inc), or flow cytometry (FACSCalibur, BD Bioscience, Franklin Lakes, NJ, USA) at excitation wavelength of 488 nm and an emission wavelength of 520 nm to determine the change in intracellular Ca<sup>2+</sup> concentration.</p></sec><sec id="s4-15"><title>PLCE1 pull-down and phospholipase activity assay</title><p>Protein pull-down was performed using a previously reported method (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). HEK293 cells were transfected with plasmids expressing either PLCE1-Myc or TAK1. 24 hr post-transfection, the cells were harvested for preparing total cell lysates, which was then subjected to protein pull-down assay using the Myc-Tag beads (Sepharose Bead Conjugate; #55464; CST, Beverley, MA, USA). After 4 hr of incubation on a rotator, the unbound proteins were removed using ice-cold wash buffer. Finally, phospholipase activity bound to the beads was detected using a PLC Activity Assay Kit (Jining Shiye, Shanghai, China) according to the manufacturer’s protocol. PLC catalyzes the hydrolysis of <italic>O</italic>-(4-nitrophenyl) choline to produce <italic>p</italic>-nitrophenol (PNP), which has an absorption maximum at 405 nm. The magnitude of the PLC enzyme activity was calculated by detecting the rate of increase in PNP at 405 nm.</p></sec><sec id="s4-16"><title>IP3 and DAG assays</title><p>IP3 and DAG levels in the cells were assayed using a Human Inositol 1,4,5-triphosphate enzyme-linked Immunosorbent Assay (ELISA) Kit and a Human Diacylglycerol commercial ELISA Kit (Mlbio, Shanghai, China), according to the manufacturer’s instructions. The absorbance was measured at 450 nm using a microplate reader.</p></sec><sec id="s4-17"><title>Co-immunoprecipitation and MS/MS spectrometry</title><p>Co-immunoprecipitation and MS/MS assays were performed as described previously (<xref ref-type="bibr" rid="bib40">Shi et al., 2021</xref>). Briefly, ECA-109 cells were transfected with a plasmid expressing <italic>Map3k7</italic>. At 36 hr post-transfection, cells were harvested for co-immunoprecipitation using an antibody against TAK1. The resulting immunocomplex was subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Shanghai Applied Protein Technology Co., Ltd.). MS/MS spectra were searched using the MASCOT engine (Matrix Science, London, UK; version 2.4) against UniProKB human (161584 total entries, downloaded 20180105).</p></sec><sec id="s4-18"><title>Mouse xenograft metastasis model</title><p>For in vivo metastasis assay, 4-week-old male BALB/c nude mice (18–20 g) were purchased from Shanghai Slake Laboratory Animal Co., Ltd. (Shanghai, China) and randomly divided into two groups (n=6–10 per group). Mice meeting strict inclusion criteria (age-matched males, 18–20 g, normal baseline behavior) were housed in air-filtered laminar flow cages (5 mice/cage) with a 12 hr light cycle and adequate food and water. To examine the role of PLCE1 on metastasis, each mouse was intravenously (i.v.) injected with 1×10<sup>6</sup> ECA-109 cells diluted in 100 µl PBS, which were transduced with LV-shPLCE1 or negative control virus. Additionally, to examine TAK1 inhibition on metastasis, each mouse was i.v. injected with 1×10<sup>6</sup> ECA-109 cells. The mice were then intraperitoneally injected with Takinib (50 mg/kg/day) or vehicle (corn oil) for 15 days. Blinded investigators performed all outcome assessments while separate personnel conducted treatments. Animals showing &gt;15% weight loss or distress were excluded per protocol. The body weight of the mice was measured once per week. Eight weeks later, the mice were sacrificed, and the lungs and livers were collected for further analysis. All animal experiments were performed in accordance with the institutional ethical guidelines for animal care, and approved by the Animal Experimentation Ethics Committee of Nantong University (Approval ID: SYXK (SU) 2017-0046).</p></sec><sec id="s4-19"><title>Statistical analysis</title><p>Statistical significance of differences between groups were tested by using analysis of variance (ANOVA) or unpaired Student’s t<italic>-</italic>test. Data were presented as mean ± SD from at least three independent experiments. All statistical analyses were performed using GraphPad Prism version 8.0 (GraphPad Software, La Jolla, CA, USA). *p&lt;0.05 was accepted as statistical significance.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Validation, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources, Validation</p></fn><fn fn-type="con" id="con5"><p>Resources</p></fn><fn fn-type="con" id="con6"><p>Methodology</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Project administration</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human esophageal squamous tumor specimens were obtained from the Affiliated Hospital of Nantong University. All samples were collected with written informed consent from patients and in compliance with the ethical principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Ethics Committee of the Affiliated Hospital of Nantong University (approval number: 2015 L132).</p></fn><fn fn-type="other"><p>All animal experiments were performed in accordance with the institutional ethical guidelines for animal care, and approved by the Animal Experimentation Ethics Committee of Nantong University (Approval ID: SYXK (SU) 2017-0046).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>he sequences used in gene knockdown and mutation.</title></caption><media xlink:href="elife-97373-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Primer sequences used in quantitative real time-PCR (qRT-PCR).</title></caption><media xlink:href="elife-97373-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-97373-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The dataset regarding MS-based protein phosphorylation modifications can be found in figshare <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.25271140">https://doi.org/10.6084/m9.figshare.25271140</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>LC-MS/MS spectrometry analysis of PLCE1</data-title><source>figshare</source><pub-id pub-id-type="doi">10.6084/m9.figshare.25271140</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to thank Friedhelm Hildebrandt from University of Michigan Drive for providing the plasmid expressing PLCE1.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abnet</surname><given-names>CC</given-names></name><name><surname>Freedman</surname><given-names>ND</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name><name><surname>Yuan</surname><given-names>JM</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Dawsey</surname><given-names>SM</given-names></name><name><surname>Dong</surname><given-names>LM</given-names></name><name><surname>Lee</surname><given-names>MP</given-names></name><name><surname>Ding</surname><given-names>T</given-names></name><name><surname>Qiao</surname><given-names>YL</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>Koh</surname><given-names>WP</given-names></name><name><surname>Xiang</surname><given-names>YB</given-names></name><name><surname>Tang</surname><given-names>ZZ</given-names></name><name><surname>Fan</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wheeler</surname><given-names>W</given-names></name><name><surname>Gail</surname><given-names>MH</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Yuenger</surname><given-names>J</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><name><surname>Jacobs</surname><given-names>KB</given-names></name><name><surname>Giffen</surname><given-names>CA</given-names></name><name><surname>Burdett</surname><given-names>L</given-names></name><name><surname>Fraumeni</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Tucker</surname><given-names>MA</given-names></name><name><surname>Chow</surname><given-names>WH</given-names></name><name><surname>Goldstein</surname><given-names>AM</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma</article-title><source>Nature Genetics</source><volume>42</volume><fpage>764</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1038/ng.649</pub-id><pub-id pub-id-type="pmid">20729852</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhikari</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Ubiquitin-mediated activation of TAK1 and IKK</article-title><source>Oncogene</source><volume>26</volume><fpage>3214</fpage><lpage>3226</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210413</pub-id><pub-id pub-id-type="pmid">17496917</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augeri</surname><given-names>DJ</given-names></name><name><surname>Langenfeld</surname><given-names>E</given-names></name><name><surname>Castle</surname><given-names>M</given-names></name><name><surname>Gilleran</surname><given-names>JA</given-names></name><name><surname>Langenfeld</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death</article-title><source>Molecular Cancer</source><volume>15</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-016-0511-9</pub-id><pub-id pub-id-type="pmid">27048361</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunney</surname><given-names>TD</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Phosphoinositide signalling in cancer: beyond PI3K and PTEN</article-title><source>Nature Reviews. Cancer</source><volume>10</volume><fpage>342</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1038/nrc2842</pub-id><pub-id pub-id-type="pmid">20414202</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>PCH</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>VWS</given-names></name><name><surname>Tang</surname><given-names>HWM</given-names></name><name><surname>Liu</surname><given-names>IJ</given-names></name><name><surname>Leung</surname><given-names>THY</given-names></name><name><surname>Chan</surname><given-names>KKL</given-names></name><name><surname>Yam</surname><given-names>JWP</given-names></name><name><surname>Yao</surname><given-names>K-M</given-names></name><name><surname>Ngan</surname><given-names>HYS</given-names></name><name><surname>Chan</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling</article-title><source>Oncotarget</source><volume>5</volume><fpage>7549</fpage><lpage>7562</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2273</pub-id><pub-id pub-id-type="pmid">25277189</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaib</surname><given-names>H</given-names></name><name><surname>Hoskins</surname><given-names>BE</given-names></name><name><surname>Ashraf</surname><given-names>S</given-names></name><name><surname>Goyal</surname><given-names>M</given-names></name><name><surname>Wiggins</surname><given-names>RC</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Identification of BRAF as a new interactor of PLCepsilon1, the protein mutated in nephrotic syndrome type 3</article-title><source>American Journal of Physiology. Renal Physiology</source><volume>294</volume><fpage>F93</fpage><lpage>F99</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00345.2007</pub-id><pub-id pub-id-type="pmid">17942568</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLCε-NF-κB signaling pathway and VEGF-C/ Bcl-2 expression</article-title><source>Molecular Cancer</source><volume>18</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-018-0930-x</pub-id><pub-id pub-id-type="pmid">30609930</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xin</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hypomethylation-linked activation of PLCE1 impedes autophagy and promotes tumorigenesis through MDM2-mediated ubiquitination and destabilization of p53</article-title><source>Cancer Research</source><volume>80</volume><fpage>2175</fpage><lpage>2189</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-1912</pub-id><pub-id pub-id-type="pmid">32066565</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Shim</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>MR</given-names></name><name><surname>Choi</surname><given-names>JN</given-names></name><name><surname>Akanda</surname><given-names>MR</given-names></name><name><surname>Hwang</surname><given-names>JE</given-names></name><name><surname>Bae</surname><given-names>WK</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Sun</surname><given-names>EG</given-names></name><name><surname>Chung</surname><given-names>IJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Lgals3bp suppresses colon inflammation and tumorigenesis through the downregulation of TAK1-NF-κB signaling</article-title><source>Cell Death Discovery</source><volume>7</volume><elocation-id>65</elocation-id><pub-id pub-id-type="doi">10.1038/s41420-021-00447-7</pub-id><pub-id pub-id-type="pmid">33824294</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duong</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Teng</surname><given-names>B</given-names></name><name><surname>Schroder</surname><given-names>P</given-names></name><name><surname>Haller</surname><given-names>H</given-names></name><name><surname>Eschenburg</surname><given-names>S</given-names></name><name><surname>Schiffer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Protein kinase C ϵ stabilizes β-catenin and regulates its subcellular localization in podocytes</article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>12100</fpage><lpage>12110</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.775700</pub-id><pub-id pub-id-type="pmid">28539358</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Niu</surname><given-names>L</given-names></name><name><surname>Duan</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PLCε regulates prostate cancer mitochondrial oxidative metabolism and migration via upregulation of Twist1</article-title><source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>38</volume><elocation-id>337</elocation-id><pub-id pub-id-type="doi">10.1186/s13046-019-1323-8</pub-id><pub-id pub-id-type="pmid">31383001</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fife</surname><given-names>CM</given-names></name><name><surname>McCarroll</surname><given-names>JA</given-names></name><name><surname>Kavallaris</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Movers and shakers: cell cytoskeleton in cancer metastasis</article-title><source>British Journal of Pharmacology</source><volume>171</volume><fpage>5507</fpage><lpage>5523</lpage><pub-id pub-id-type="doi">10.1111/bph.12704</pub-id><pub-id pub-id-type="pmid">24665826</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiki</surname><given-names>T</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Maura</surname><given-names>M</given-names></name><name><surname>Shiraishi</surname><given-names>H</given-names></name><name><surname>Nishimura</surname><given-names>S</given-names></name><name><surname>Imada</surname><given-names>Y</given-names></name><name><surname>Uehara</surname><given-names>N</given-names></name><name><surname>Tashiro</surname><given-names>K</given-names></name><name><surname>Shirahata</surname><given-names>S</given-names></name><name><surname>Katakura</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>TAK1 represses transcription of the human telomerase reverse transcriptase gene</article-title><source>Oncogene</source><volume>26</volume><fpage>5258</fpage><lpage>5266</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210331</pub-id><pub-id pub-id-type="pmid">17325661</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukami</surname><given-names>K</given-names></name><name><surname>Inanobe</surname><given-names>S</given-names></name><name><surname>Kanemaru</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Phospholipase C is a key enzyme regulating intracellular calcium and modulating the phosphoinositide balance</article-title><source>Progress in Lipid Research</source><volume>49</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.plipres.2010.06.001</pub-id><pub-id pub-id-type="pmid">20553968</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Nataraj</surname><given-names>NB</given-names></name><name><surname>Noronha</surname><given-names>A</given-names></name><name><surname>Patkar</surname><given-names>S</given-names></name><name><surname>Sekar</surname><given-names>A</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Winograd-Katz</surname><given-names>S</given-names></name><name><surname>Kramarski</surname><given-names>L</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Lindzen</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>DD</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Eisenberg</surname><given-names>G</given-names></name><name><surname>Gil-Henn</surname><given-names>H</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Lender</surname><given-names>Y</given-names></name><name><surname>Weiss</surname><given-names>S</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name><name><surname>Lotem</surname><given-names>M</given-names></name><name><surname>Geiger</surname><given-names>B</given-names></name><name><surname>Ruppin</surname><given-names>E</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR</article-title><source>Cell Reports</source><volume>35</volume><elocation-id>109181</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109181</pub-id><pub-id pub-id-type="pmid">34038737</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Xin</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Qiang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evaluation of GWAS-identified genetic variants for gastric cancer survival</article-title><source>EBioMedicine</source><volume>33</volume><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.06.028</pub-id><pub-id pub-id-type="pmid">29983348</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Woodfield</surname><given-names>SE</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Bieerkehazhi</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis</article-title><source>Oncotarget</source><volume>8</volume><fpage>33666</fpage><lpage>33675</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16895</pub-id><pub-id pub-id-type="pmid">28430599</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Suo</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Suppression of HSP70 inhibits the development of acute lymphoblastic leukemia via TAK1/Egr-1</article-title><source>Biomedicine &amp; Pharmacotherapy = Biomedecine &amp; Pharmacotherapie</source><volume>119</volume><elocation-id>109399</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109399</pub-id><pub-id pub-id-type="pmid">31521893</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gwak</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>SJ</given-names></name><name><surname>Won</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>DE</given-names></name><name><surname>Kim</surname><given-names>EY</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>TK</given-names></name><name><surname>Shin</surname><given-names>JG</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the Wnt/beta-catenin pathway</article-title><source>Journal of Cell Science</source><volume>119</volume><fpage>4702</fpage><lpage>4709</lpage><pub-id pub-id-type="doi">10.1242/jcs.03256</pub-id><pub-id pub-id-type="pmid">17093267</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harden</surname><given-names>TK</given-names></name><name><surname>Hicks</surname><given-names>SN</given-names></name><name><surname>Sondek</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Phospholipase C isozymes as effectors of Ras superfamily GTPases</article-title><source>Journal of Lipid Research</source><volume>50 Suppl</volume><fpage>S243</fpage><lpage>S248</lpage><pub-id pub-id-type="doi">10.1194/jlr.R800045-JLR200</pub-id><pub-id pub-id-type="pmid">19033212</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genetic variant PLCE1 rs2274223 and gastric cancer: more to be explored?</article-title><source>Gut</source><volume>65</volume><fpage>359</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-309968</pub-id><pub-id pub-id-type="pmid">26078291</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Advances and challenges in the treatment of esophageal cancer</article-title><source>Acta Pharmaceutica Sinica. B</source><volume>11</volume><fpage>3379</fpage><lpage>3392</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.03.008</pub-id><pub-id pub-id-type="pmid">34900524</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Karnes</surname><given-names>RJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jimenez</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>MAP3K7-IKK inflammatory signaling modulates AR protein degradation and prostate cancer progression</article-title><source>Cancer Research</source><volume>81</volume><fpage>4471</fpage><lpage>4484</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-4194</pub-id><pub-id pub-id-type="pmid">34158377</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadamur</surname><given-names>G</given-names></name><name><surname>Ross</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mammalian phospholipase C</article-title><source>Annual Review of Physiology</source><volume>75</volume><fpage>127</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-030212-183750</pub-id><pub-id pub-id-type="pmid">23140367</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Son</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Chun</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>FFAR2 antagonizes TLR2- and TLR3-induced lung cancer progression via the inhibition of AMPK-TAK1 signaling axis for the activation of NF-κB</article-title><source>Cell &amp; Bioscience</source><volume>13</volume><elocation-id>102</elocation-id><pub-id pub-id-type="doi">10.1186/s13578-023-01038-y</pub-id><pub-id pub-id-type="pmid">37287005</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagergren</surname><given-names>J</given-names></name><name><surname>Smyth</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Lagergren</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oesophageal cancer</article-title><source>Lancet</source><volume>390</volume><fpage>2383</fpage><lpage>2396</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31462-9</pub-id><pub-id pub-id-type="pmid">28648400</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Land</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A calcium- and diacylglycerol-stimulated protein kinase C (PKC), <italic>Caenorhabditis elegans</italic> PKC-2, links thermal signals to learned behavior by acting in sensory neurons and intestinal cells</article-title><source>Molecular and Cellular Biology</source><volume>37</volume><elocation-id>e00192-17</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00192-17</pub-id><pub-id pub-id-type="pmid">28716951</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanical tumor microenvironment and transduction: cytoskeleton mediates cancer cell invasion and metastasis</article-title><source>International Journal of Biological Sciences</source><volume>16</volume><fpage>2014</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.7150/ijbs.44943</pub-id><pub-id pub-id-type="pmid">32549750</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Peng</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy</article-title><source>Oncotarget</source><volume>8</volume><fpage>29202</fpage><lpage>29219</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16346</pub-id><pub-id pub-id-type="pmid">28418898</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>MTV</given-names></name><name><surname>Peng</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Sham</surname><given-names>KWY</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ho</surname><given-names>IHT</given-names></name><name><surname>Gin</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>WKK</given-names></name><name><surname>Cheng</surname><given-names>CHK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Developmental protein kinase C hyper-activation results in microcephaly and behavioral abnormalities in zebrafish</article-title><source>Translational Psychiatry</source><volume>8</volume><elocation-id>232</elocation-id><pub-id pub-id-type="doi">10.1038/s41398-018-0285-5</pub-id><pub-id pub-id-type="pmid">30352990</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion</article-title><source>Cancer Cell</source><volume>4</volume><fpage>499</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/s1535-6108(03)00304-0</pub-id><pub-id pub-id-type="pmid">14706341</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>LE</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Sturgis</surname><given-names>EM</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Association between novel PLCE1 variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck</article-title><source>BMC Cancer</source><volume>11</volume><elocation-id>258</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-11-258</pub-id><pub-id pub-id-type="pmid">21689432</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Luan</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mechanisms of pharmaceutical therapy and drug resistance in esophageal cancer</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>612451</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.612451</pub-id><pub-id pub-id-type="pmid">33644048</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>NY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multifaceted roles of TAK1 signaling in cancer</article-title><source>Oncogene</source><volume>39</volume><fpage>1402</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1038/s41388-019-1088-8</pub-id><pub-id pub-id-type="pmid">31695153</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RNA interference suppressing PLCE1 gene expression decreases invasive power of human bladder cancer T24 cell line</article-title><source>Cancer Genetics and Cytogenetics</source><volume>200</volume><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2010.01.021</pub-id><pub-id pub-id-type="pmid">20620593</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennathur</surname><given-names>A</given-names></name><name><surname>Gibson</surname><given-names>MK</given-names></name><name><surname>Jobe</surname><given-names>BA</given-names></name><name><surname>Luketich</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Oesophageal carcinoma</article-title><source>Lancet</source><volume>381</volume><fpage>400</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60643-6</pub-id><pub-id pub-id-type="pmid">23374478</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>JM</given-names></name><name><surname>Han</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Autotaxin-LPA axis regulates hMSC migration by adherent junction disruption and cytoskeletal rearrangement via LPAR1/3-dependent PKC/GSK3β/β-catenin and PKC/Rho GTPase pathways</article-title><source>Stem Cells</source><volume>33</volume><fpage>819</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1002/stem.1882</pub-id><pub-id pub-id-type="pmid">25376707</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Targeting of TAK1 in inflammatory disorders and cancer</article-title><source>Trends in Pharmacological Sciences</source><volume>33</volume><fpage>522</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2012.06.007</pub-id><pub-id pub-id-type="pmid">22795313</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>R</given-names></name><name><surname>Zanotto</surname><given-names>M</given-names></name><name><surname>Simionato</surname><given-names>F</given-names></name><name><surname>Zecchetto</surname><given-names>C</given-names></name><name><surname>Merz</surname><given-names>V</given-names></name><name><surname>Cavallini</surname><given-names>C</given-names></name><name><surname>Piro</surname><given-names>G</given-names></name><name><surname>Sabbadini</surname><given-names>F</given-names></name><name><surname>Boschi</surname><given-names>F</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Melisi</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer</article-title><source>Molecular Cancer Therapeutics</source><volume>19</volume><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-0270</pub-id><pub-id pub-id-type="pmid">31562256</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Ju</surname><given-names>Q</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TAK1 Phosphorylates RASSF9 and inhibits esophageal squamous tumor cell proliferation by targeting the RAS/MEK/ERK Axis</article-title><source>Advanced Science</source><volume>8</volume><elocation-id>2001575</elocation-id><pub-id pub-id-type="doi">10.1002/advs.202001575</pub-id><pub-id pub-id-type="pmid">33717835</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skaug</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The role of ubiquitin in NF-kappaB regulatory pathways</article-title><source>Annual Review of Biochemistry</source><volume>78</volume><fpage>769</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.78.070907.102750</pub-id><pub-id pub-id-type="pmid">19489733</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smrcka</surname><given-names>AV</given-names></name><name><surname>Brown</surname><given-names>JH</given-names></name><name><surname>Holz</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of phospholipase Cε in physiological phosphoinositide signaling networks</article-title><source>Cellular Signalling</source><volume>24</volume><fpage>1333</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2012.01.009</pub-id><pub-id pub-id-type="pmid">22286105</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorrentino</surname><given-names>A</given-names></name><name><surname>Thakur</surname><given-names>N</given-names></name><name><surname>Grimsby</surname><given-names>S</given-names></name><name><surname>Marcusson</surname><given-names>A</given-names></name><name><surname>von Bulow</surname><given-names>V</given-names></name><name><surname>Schuster</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Heldin</surname><given-names>C-H</given-names></name><name><surname>Landström</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner</article-title><source>Nature Cell Biology</source><volume>10</volume><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1038/ncb1780</pub-id><pub-id pub-id-type="pmid">18758450</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Bu</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>TAK1 deficiency promotes liver injury and tumorigenesis via ferroptosis and macrophage cGAS-STING signalling</article-title><source>JHEP Reports</source><volume>5</volume><elocation-id>100695</elocation-id><pub-id pub-id-type="doi">10.1016/j.jhepr.2023.100695</pub-id><pub-id pub-id-type="pmid">36968217</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA</source><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Niu</surname><given-names>K</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma</article-title><source>PNAS</source><volume>117</volume><fpage>14231</fpage><lpage>14242</lpage><pub-id pub-id-type="doi">10.1073/pnas.2005353117</pub-id><pub-id pub-id-type="pmid">32513687</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>R</given-names></name><name><surname>Krueger</surname><given-names>RK</given-names></name><name><surname>Gramelspacher</surname><given-names>MJ</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Ke</surname><given-names>A</given-names></name><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems</article-title><source>Molecular Cell</source><volume>82</volume><fpage>852</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.12.032</pub-id><pub-id pub-id-type="pmid">35051351</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tejeda-Muñoz</surname><given-names>N</given-names></name><name><surname>González-Aguilar</surname><given-names>H</given-names></name><name><surname>Santoyo-Ramos</surname><given-names>P</given-names></name><name><surname>Castañeda-Patlán</surname><given-names>MC</given-names></name><name><surname>Robles-Flores</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glycogen synthase kinase 3β Is positively regulated by protein kinase Cζ-Mediated Phosphorylation Induced by Wnt Agonists</article-title><source>Molecular and Cellular Biology</source><volume>36</volume><fpage>731</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1128/MCB.00828-15</pub-id><pub-id pub-id-type="pmid">26711256</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>V</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Stuelten</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>YE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance</article-title><source>Oncogene</source><volume>38</volume><fpage>3185</fpage><lpage>3200</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0655-8</pub-id><pub-id pub-id-type="pmid">30626936</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenta</surname><given-names>T</given-names></name><name><surname>Hausmann</surname><given-names>G</given-names></name><name><surname>Basler</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The many faces and functions of β-catenin</article-title><source>The EMBO Journal</source><volume>31</volume><fpage>2714</fpage><lpage>2736</lpage><pub-id pub-id-type="doi">10.1038/emboj.2012.150</pub-id><pub-id pub-id-type="pmid">22617422</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LD</given-names></name><name><surname>Zhou</surname><given-names>FY</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Sun</surname><given-names>LD</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>JM</given-names></name><name><surname>Kong</surname><given-names>GQ</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>LQ</given-names></name><name><surname>Yang</surname><given-names>JZ</given-names></name><name><surname>Li</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>XC</given-names></name><name><surname>Ren</surname><given-names>JL</given-names></name><name><surname>Liu</surname><given-names>ZC</given-names></name><name><surname>Gao</surname><given-names>WJ</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>YR</given-names></name><name><surname>Wang</surname><given-names>WP</given-names></name><name><surname>Sheyhidin</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>BP</given-names></name><name><surname>Ren</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Ku</surname><given-names>JW</given-names></name><name><surname>Fan</surname><given-names>ZM</given-names></name><name><surname>Zhou</surname><given-names>SL</given-names></name><name><surname>Guo</surname><given-names>ZG</given-names></name><name><surname>Zhao</surname><given-names>XK</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Ai</surname><given-names>YH</given-names></name><name><surname>Shen</surname><given-names>FF</given-names></name><name><surname>Cui</surname><given-names>WY</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>WB</given-names></name><name><surname>Feng</surname><given-names>CW</given-names></name><name><surname>Li</surname><given-names>HL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>JY</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>WL</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Fu</surname><given-names>WJ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><name><surname>Han</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Dong</surname><given-names>JC</given-names></name><name><surname>Xing</surname><given-names>GL</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>ZW</given-names></name><name><surname>Liu</surname><given-names>HL</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>ZQ</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>LQ</given-names></name><name><surname>Zhu</surname><given-names>FG</given-names></name><name><surname>Yang</surname><given-names>XF</given-names></name><name><surname>Feng</surname><given-names>XS</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>SG</given-names></name><name><surname>Qige</surname><given-names>Q</given-names></name><name><surname>Bai</surname><given-names>LT</given-names></name><name><surname>Yang</surname><given-names>WJ</given-names></name><name><surname>Lei</surname><given-names>GY</given-names></name><name><surname>Shen</surname><given-names>ZY</given-names></name><name><surname>Chen</surname><given-names>LQ</given-names></name><name><surname>Li</surname><given-names>EM</given-names></name><name><surname>Xu</surname><given-names>LY</given-names></name><name><surname>Wu</surname><given-names>ZY</given-names></name><name><surname>Cao</surname><given-names>WK</given-names></name><name><surname>Wang</surname><given-names>JP</given-names></name><name><surname>Bao</surname><given-names>ZQ</given-names></name><name><surname>Chen</surname><given-names>JL</given-names></name><name><surname>Ding</surname><given-names>GC</given-names></name><name><surname>Zhuang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>YF</given-names></name><name><surname>Zheng</surname><given-names>HF</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zuo</surname><given-names>XB</given-names></name><name><surname>Dong</surname><given-names>ZM</given-names></name><name><surname>Fan</surname><given-names>DM</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>QX</given-names></name><name><surname>Jiao</surname><given-names>XY</given-names></name><name><surname>Lian</surname><given-names>SY</given-names></name><name><surname>Ji</surname><given-names>AF</given-names></name><name><surname>Lu</surname><given-names>XM</given-names></name><name><surname>Wang</surname><given-names>JS</given-names></name><name><surname>Chang</surname><given-names>FB</given-names></name><name><surname>Lu</surname><given-names>CD</given-names></name><name><surname>Chen</surname><given-names>ZG</given-names></name><name><surname>Miao</surname><given-names>JJ</given-names></name><name><surname>Fan</surname><given-names>ZL</given-names></name><name><surname>Lin</surname><given-names>RB</given-names></name><name><surname>Liu</surname><given-names>TJ</given-names></name><name><surname>Wei</surname><given-names>JC</given-names></name><name><surname>Kong</surname><given-names>QP</given-names></name><name><surname>Lan</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>YJ</given-names></name><name><surname>Gao</surname><given-names>FS</given-names></name><name><surname>Wang</surname><given-names>TY</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>SQ</given-names></name><name><surname>Yang</surname><given-names>WC</given-names></name><name><surname>Hong</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Qiu</surname><given-names>SL</given-names></name><name><surname>Cai</surname><given-names>ZM</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54</article-title><source>Nature Genetics</source><volume>42</volume><fpage>759</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1038/ng.648</pub-id><pub-id pub-id-type="pmid">20729853</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XK</given-names></name><name><surname>Liao</surname><given-names>XW</given-names></name><name><surname>Yang</surname><given-names>CK</given-names></name><name><surname>Liu</surname><given-names>ZQ</given-names></name><name><surname>Han</surname><given-names>QF</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>LB</given-names></name><name><surname>Deng</surname><given-names>T</given-names></name><name><surname>Gong</surname><given-names>YZ</given-names></name><name><surname>Huang</surname><given-names>JL</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>CY</given-names></name><name><surname>Yu</surname><given-names>TD</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>XP</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>GZ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines</article-title><source>Journal of Cellular Physiology</source><volume>235</volume><fpage>7003</fpage><lpage>7017</lpage><pub-id pub-id-type="doi">10.1002/jcp.29596</pub-id><pub-id pub-id-type="pmid">32037547</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>ZB</given-names></name><name><surname>Yang</surname><given-names>PJ</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>JL</given-names></name><name><surname>Ruan</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Yue</surname><given-names>ZS</given-names></name><name><surname>Fang</surname><given-names>ZQ</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>XL</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>KS</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Dou</surname><given-names>KF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1</article-title><source>Cell Metabolism</source><volume>33</volume><fpage>1372</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.05.019</pub-id><pub-id pub-id-type="pmid">34146477</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Cimic</surname><given-names>A</given-names></name><name><surname>Romero</surname><given-names>L</given-names></name><name><surname>Sui</surname><given-names>G</given-names></name><name><surname>Lees</surname><given-names>CJ</given-names></name><name><surname>Cline</surname><given-names>JM</given-names></name><name><surname>Seals</surname><given-names>DF</given-names></name><name><surname>Sirintrapun</surname><given-names>JS</given-names></name><name><surname>McCoy</surname><given-names>TP</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Hawkins</surname><given-names>GA</given-names></name><name><surname>Peehl</surname><given-names>DM</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Cramer</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Suppression of Tak1 promotes prostate tumorigenesis</article-title><source>Cancer Research</source><volume>72</volume><fpage>2833</fpage><lpage>2843</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-2724</pub-id><pub-id pub-id-type="pmid">22467172</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Tao</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Wan</surname><given-names>Z</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TAK1 is a novel target in hepatocellular carcinoma and contributes to sorafenib resistance</article-title><source>Cellular and Molecular Gastroenterology and Hepatology</source><volume>12</volume><fpage>1121</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2021.04.016</pub-id><pub-id pub-id-type="pmid">33962073</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Dyck</surname><given-names>JRB</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Morishima</surname><given-names>M</given-names></name><name><surname>Mann</surname><given-names>DL</given-names></name><name><surname>Taffet</surname><given-names>GE</given-names></name><name><surname>Baldini</surname><given-names>A</given-names></name><name><surname>Khoury</surname><given-names>DS</given-names></name><name><surname>Schneider</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway</article-title><source>PNAS</source><volume>103</volume><fpage>17378</fpage><lpage>17383</lpage><pub-id pub-id-type="doi">10.1073/pnas.0604708103</pub-id><pub-id pub-id-type="pmid">17085580</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Niu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>HDAC6-dependent deacetylation of TAK1 enhances sIL-6R release to promote macrophage M2 polarization in colon cancer</article-title><source>Cell Death &amp; Disease</source><volume>13</volume><elocation-id>888</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-022-05335-1</pub-id><pub-id pub-id-type="pmid">36270986</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Eupalinolide B attenuates lipopolysaccharide-induced acute lung injury through inhibition of NF-κB and MAPKs signaling by targeting TAK1 protein</article-title><source>International Immunopharmacology</source><volume>111</volume><elocation-id>109148</elocation-id><pub-id pub-id-type="doi">10.1016/j.intimp.2022.109148</pub-id><pub-id pub-id-type="pmid">35988521</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>QY</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>XL</given-names></name><name><surname>Zhang</surname><given-names>YH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PLCE1 inhibits apoptosis of non-small cell lung cancer via promoting PTEN methylation</article-title><source>European Review for Medical and Pharmacological Sciences</source><volume>23</volume><fpage>6211</fpage><lpage>6216</lpage><pub-id pub-id-type="doi">10.26355/eurrev_201907_18438</pub-id><pub-id pub-id-type="pmid">31364122</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Liao</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Luan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Androgen signaling contributes to sex differences in cancer by inhibiting NF-κB activation in T cells and suppressing antitumor immunity</article-title><source>Cancer Research</source><volume>83</volume><fpage>906</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-22-2405</pub-id><pub-id pub-id-type="pmid">36634207</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhuang</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Hang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TRAF3 mediates neuronal apoptosis in early brain injury following subarachnoid hemorrhage via targeting TAK1-dependent MAPKs and NF-κB pathways</article-title><source>Cell Death &amp; Disease</source><volume>12</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-03278-z</pub-id><pub-id pub-id-type="pmid">33414375</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Lama</surname><given-names>S</given-names></name><name><surname>Tu</surname><given-names>L</given-names></name><name><surname>Dusting</surname><given-names>GJ</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name><name><surname>Liu</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TAK1 signaling is a potential therapeutic target for pathological angiogenesis</article-title><source>Angiogenesis</source><volume>24</volume><fpage>453</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1007/s10456-021-09787-5</pub-id><pub-id pub-id-type="pmid">33973075</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>Map3k7</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">Gene ID:6885</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>Plce1</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">Gene ID: 51196</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">DH5α</td><td align="left" valign="bottom">Vazyme</td><td align="left" valign="bottom">C502</td><td align="left" valign="bottom">Competent cells</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">ECA-109</td><td align="left" valign="bottom">SIBCB</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.cellbank.org.cn/search-detail.php?id=147">TCHu69</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">KYSE-150</td><td align="left" valign="bottom">SIBCB</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.cellbank.org.cn/search-detail.php?id=540">TCHu236</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">TE-1</td><td align="left" valign="bottom">SIBCB</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.cellbank.org.cn/search-detail.php?id=167">TCHu 89</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK-293</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1573</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom"><italic>Map3k7</italic><break/>shRNA/ shNC</td><td align="left" valign="bottom">Hanbio</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Lentiviral construct to transfect <break/>and express the shRNA.</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom"><italic>Plce1</italic><break/>shRNA/shNC</td><td align="left" valign="bottom">OBiO</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Lentiviral construct to transfect <break/>and express the shRNA.</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to <italic>Map3k7</italic></td><td align="left" valign="bottom">RiboBio</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Transfected construct <break/>(human)</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to <italic>Plce1</italic></td><td align="left" valign="bottom">RiboBio</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Transfected construct <break/>(human)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-TAK1 (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 5206</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho- TAK1 (Ser412) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 9339</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PLCE1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#: PA5-100856</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-PLCE1 (Ser1060) (Rabbit polyclonal)</td><td align="left" valign="bottom">Absin</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">WB (1:1000)<break/>IHC (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PKCα (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 2056</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-PKC (pan) (gamma Thr514) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 38938</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GSK-3β (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 9315</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-GSK-3β (Ser9) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 5558</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-β-Catenin (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 8480-</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-β-Catenin (Ser33/37/Thr41) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 9561</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-MMP-2 (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 87809-</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Actin (Mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 3700-</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Myc-Tag (Sepharose Bead Conjugate)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 55464</td><td align="left" valign="bottom">IP (1:20)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Epithelial-Mesenchymal Transition (EMT) antibody sample kit</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 9782</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-IKK (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 61294</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phosphor-IKK (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 2078</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-JNK (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 9252</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phosphor-JNK (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 4668</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-ERK (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 9102</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-ERK (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 4370</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-P38 MPAK (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 9212</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-P38 MAPK (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 9211</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-normal rabbit IgG (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 2729</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1-<italic>Map3k7</italic><break/>(plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pRK5-myc <italic>Plce1</italic><break/>(plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Dr. Friedhelm Hildebrandt (1)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Map3k7</italic> siRNA</td><td align="left" valign="bottom">RiboBio</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"><named-content content-type="sequence">GGAGTTGTTTGCAAAGCTA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Plce1</italic> siRNA-1</td><td align="left" valign="bottom">RiboBio</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"><named-content content-type="sequence">GGACTTCAATATCGCAGTA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Plce1</italic> siRNA-2</td><td align="left" valign="bottom">RiboBio</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"><named-content content-type="sequence">GTCGAAGTGTAGAATTGGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Plce1</italic> siRNA-3</td><td align="left" valign="bottom">RiboBio</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"><named-content content-type="sequence">CAATCATCATATCGATTGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Map3k7</italic> gRNA_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ccgAGGGGCTTCGATCATCTCAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Map3k7</italic> gRNA_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">aacGTGAGATGATCGAAGCCCCT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Plce1</italic> (S1060A) _F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TGGAGTGCTCGAAACCCCGCACCCGGAACATCAGCAAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Plce1</italic> (S1060A) _R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGGGTTTCGAGCACTCCACCGTCTGCCACCAAACAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Map3k7</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">ATTGTAGAGCTTCGGCAGTTATC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Map3k7</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CTGTAAACACCAACTCATTGCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Plce1</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGGTGACATGGCTGATCCTC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Plce1</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GACAGCGTTGTAGTTGCCCA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cdh1</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GCTTTACTGTTTCTCAAGTGT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cdh1</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AATACACAATTATCAGCACCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Vim</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AACTTCTCAGCATCACGAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Vim</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GTAGGAGTGTCGGTTGTT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ctnnb1</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AGAATTGAGTAATGGTGTAGAAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ctnnb1</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TACCCATACATATCCCAAATAGT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cldn1</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TGTATAGTCCTCTTGGGTTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cldn1</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AATTGTCAGTGGAGTCAGT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cdh2</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AAAAGGAAAGGAAAGAAAGGG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cdh2</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GTCAGAGGTGTATCATTTATATTCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Zeb1</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GTTGCTCCTTCTTCCTGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Zeb1</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">ATGTGGTTCCTGTTCCTAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Tjp1</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TGTGGACATCCTACTTACTTAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Tjp1</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GAGAAGATAAAGAAACTGTTGTATG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Snai1</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AGCTATTTCAG</named-content>CCTCCTG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Snai1</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TGTAAACATCTTCCTC</named-content>CCAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Snai2</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CTGTATGAAACTGAGATGTTGT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Snai2</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GAAGCAAGTAAAGTCTCTGAAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gapdh</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AAGAGCACAAGAGGAAGAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Gapdh</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TAACTGGTTGAGCACAGG</named-content></td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">PLC Activity Assay Kit</td><td align="left" valign="bottom">Jining Shiye</td><td align="left" valign="bottom">ml076627</td><td align="left" valign="bottom">ELISA kit</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Fluo-4 AM Assay Kit</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">S1060</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Human Inositol 1,4,5-triphosphate enzyme-linked Immunosorbent Assay</td><td align="left" valign="bottom">Mlbio</td><td align="left" valign="bottom">ml060362</td><td align="left" valign="bottom">ELISA kit</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Human Diacylglycerol commercial ELISA Kit</td><td align="left" valign="bottom">Mlbio</td><td align="left" valign="bottom">ml026857</td><td align="left" valign="bottom">ELISA kit</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">5Z-7-oxozeaenol</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">O9890</td><td align="left" valign="bottom">TAK1 inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NG25</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">SML1332</td><td align="left" valign="bottom">TAK1 inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Takinib</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">SML2216</td><td align="left" valign="bottom">TAK1 inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BAPTA-AM</td><td align="left" valign="bottom">MedChemExpress</td><td align="left" valign="bottom">HY-100545</td><td align="left" valign="bottom">An intracellular <break/>calcium chelator</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Midostaurin</td><td align="left" valign="bottom">MedChemExpress</td><td align="left" valign="bottom">HY-10230</td><td align="left" valign="bottom">A PKC inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-APB</td><td align="left" valign="bottom">MedChemExpress</td><td align="left" valign="bottom">HY-W009724</td><td align="left" valign="bottom">An IP3R antagonist</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">EGF</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">PHG0311</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism version 8.0</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97373.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Sameh</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Children's Cancer Hospital Egypt</institution><country>Egypt</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This work provides <bold>solid</bold> evidence that Transforming Growth Factor β Activated Kinase 1 (TAK1) regulates esophageal squamous cell carcinoma (ESCC) tumor proliferation and metastasis. The findings are <bold>valuable</bold> to the field of molecular tumor biology in general and to the understanding of ESCC tumor invasiveness and metastatic potential.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97373.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In previously published work, the authors found that Transforming Growth Factor β Activated Kinase 1 (TAK1) may regulate esophageal squamous cell carcinoma (ESCC) tumor cell proliferation via the RAS/MEK/ERK axis. They explore the mechanisms for TAK1 as a possible tumor suppressor, demonstrating phospholipase C epsilon 1 as an effector of tumor cell migration, invasion and metastatic potential.</p><p>They explore the mechanisms for TAK1 as a possible tumor suppressor, demonstrating phospholipase C epsilon 1 as an effector of tumor cell migration, invasion and metastatic potential.</p><p>Strengths:</p><p>The authors show in vitro that TAK1 overexpression reduces tumor cell migration and invasion while TAK1 knockdown promotes a mesenchymal phenotype (epithelial-mesenchymal transition) and enhances migration and invasion. To explore possible mechanisms of action, the authors focused on phospholipase C epsilon 1 (PLCE1) as a potential effector, having identified this protein in co-immunoprecipitation experiments. Further, they demonstrate that TAK1-mediated phosphorylation of PLCE1 is inhibitory. Each of the observations is supported by different experimental strategies, e.g. use of different approaches for knockdown (pharmacologic, RNA inhibition, CRISPR/Cas). Xenograft experiments showed that suppression/loss of TAK1 is associated with more frequent metastases and conversely that PLCE1 is associated positively with xenograft metastases. A considerable amount of experimental data is presented for review, including supplemental data, that show that TAK1 regulation may be important in ESCC development.</p><p>Weaknesses:</p><p>As noted by the authors, immunoprecipitation (IP) experiments identified a number (24) of proteins as potential targets for the TAK1 ser/thr kinase. Prior work (cited as Shi et al, 2021) focused on a different phosphorylation target for TAK1, Ras association domain family 9 (RASSF9), but a more comprehensive discussion of the co-IP experiments would help place this work in better context.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97373.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this study, Ju Q et al performed both in vitro and in vivo experiments to test the effect of TAK1 on cancer metastasis. They demonstrated that TAK1 is capable of directly phosphorylating PLCE1 and this modification represses its enzyme activity, leading to suppression of PIP2 hydrolysis and subsequently signal transduction in the PKC/GSK-3β/β-Catenin axis.</p><p>Strengths:</p><p>The quality of data is good, and the presentation is well organized in a logical way.</p><p>Weaknesses:</p><p>The study missed some key link in connecting the effect of TAK1 on cancer metastasis via phosphorylating PLCE1.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97373.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The research by Qianqian Ju et al. found that the knockdown of TAK1 promoted ESCC migration and invasion, whereas overexpression of TAK1 resulted in the opposite outcome. These in vitro findings could be recapitulated in a xenograft metastasis mouse model.</p><p>Mechanistically, TAK1 phosphorylates PLCE1 S1060 in the cells, decreasing PLCE1 enzyme activity and repressing PIP2 hydrolysis. As a result, reducing DAG and inositol IP3, thereby suppressing signal transduction of PKC/GSK 3β/β Catenin. Consequently, cancer metastasis-related genes were impeded by TAK1.</p><p>Overall, this study offers some intriguing observations. Providing a potential druggable target for developing agents for dealing with ESCC.</p><p>The strengths of this research are:</p><p>(1) The research uses different experimental approaches to address one question. The experiments are largely convincing and appear to be well executed.</p><p>(2) The phenotypes were observed from different angles: at the mouse model, cellular level, and molecular level.</p><p>(3) The molecular mechanism was down to a single amino acid modification on PLCE1.</p><p>The weaknesses part of this research are:</p><p>Most of the experiments were done in protein overexpression conditions, with the protein level increasing hundreds of folds in the cell, producing an artificial environment that would sometimes generate false positive results.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.97373.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ju</surname><given-names>Qianqian</given-names></name><role specific-use="author">Author</role><aff><institution>Nantong University</institution><addr-line><named-content content-type="city">Nantong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Sheng</surname><given-names>Wenjing</given-names></name><role specific-use="author">Author</role><aff><institution>Nantong University</institution><addr-line><named-content content-type="city">Nantong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Meicheng</given-names></name><role specific-use="author">Author</role><aff><institution>Nantong University</institution><addr-line><named-content content-type="city">Nantong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jing</given-names></name><role specific-use="author">Author</role><aff><institution>Nantong University</institution><addr-line><named-content content-type="city">Nantong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Liucheng</given-names></name><role specific-use="author">Author</role><aff><institution>Nantong University</institution><addr-line><named-content content-type="city">Nantong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiaoyu</given-names></name><role specific-use="author">Author</role><aff><institution>Nantong University</institution><addr-line><named-content content-type="city">Nantong</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Fang</surname><given-names>Wentao</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Chest Hospital</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Hui</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Chest Hospital</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Cheng</given-names></name><role specific-use="author">Author</role><aff><institution>Nantong University</institution><addr-line><named-content content-type="city">Nantong</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p></disp-quote><p>We would like to see the reviewers' critiques be addressed satisfactorily.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>While the manuscript reads fairly well, there are a number of minor grammatical edits that would improve the reading of this paper.</p></disp-quote><p>To improve the reading, we sent our manuscript out for language polishing using Wiley Editing Services. The changes were labeled in Red color.</p><disp-quote content-type="editor-comment"><p>The opening paragraph, while seeking to establish clinical relevance, likely can be removed or tailored.</p></disp-quote><p>We agreed with this concern, the first paragraph was tailored in the revised manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Although the authors provided a substantial amount of data to support the conclusion, there are several important issues to be added to strengthen the study, as highlighted below:</p><p>Figure 2: In this figure, the authors provided evidence that TAK1 phosphorylates PLCE1 at serine 1060. To make the data more convincing, the authors need to perform an in vitro kinase assay to confirm this result. Ideally, the in vitro kinase assay also includes a mutant form of PLCE1-S1060A as a control.</p></disp-quote><p>Thank the referee for this constructive comment. Since we cannot perform experiments with radioactive compounds in our institute, therefore the phosphorylation of PLCE1 at serine 1060 induced by TAK1 cannot be further confirmed by a routine in vitro kinase, in which 32P was used. Instead, we performed TAK1 and PLCE1 pulldown, and incubated these two proteins in a kinase assay buffer. The resulting samples were analyzed by western blot. Our data showed that TAK1 phosphorylates PLCE1 at serine 1060, as evidenced by a strong band for p-PLCE1 S1060 when TAK1 incubated with PLCE1. For the sample contained TAK1 and PLCE1 S1060A, the band density for p-PLCE1 S1060 was largely decreased. Ideally, there should be no band for p-PLCE1 S1060 when TAK1 incubated with PLCE1 S1060A. However, our current data detected p-PLCE1 S1060 in this reaction, although it was decreased as compared to wild type PLCE1. The reason for this is likely due to the presence of endogenous wild type PLCE1 in the TAK1 pull-down samples. These data were presented as Figure S6C in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Figure 4: In this part of the study, the author claimed that TAK1 inhibits PLCE1 enzyme activity. However, they fall short of evidence that this inhibitory effect of TAK1 on PLCE1 enzyme activity is mediated via phosphorylation at S1060.</p></disp-quote><p>Thank the referee for this critical comment. Actually, we measured the effect of TAK1 on mutate PLCE1 activity, which was presented in Figure 4B. The data showed that TAK1 has no inhibitory effect on PLCE1 S1060A enzyme activity. In contract, TAK1 repressed wild type PLCE1 activity (Figure 4A). These data indicate that, at least in part, the inhibitory effect of TAK1 on PLCE1 enzyme activity is mediated via phosphorylation at S1060.</p><disp-quote content-type="editor-comment"><p>Figures 6 and 7: Here the authors used ESCC metastasis model in nude mice to establish the role of TAK1 and PLCE1, respectively. However, the effects of TAK1 and PLCE1 are studied separately, and there no link to show that TAK1 inhibits metastasis via activation of PLCE1. Ideally the authors should use the transgenic mice with expression of mutant PLCE1-S1060A to support the conclusion.</p></disp-quote><p>We agreed with this notion that the transgenic mice with expression of mutant PLCE1-S1060A will further strengthen our conclusions. However, due to limited time and resource, we cannot generate such genetic mice. Thank the referee for this insightful and critical comment.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>(1) Have the authors ever checked the phosphorylation status of endogenous PLCE1 S1060p in the TAK1 overexpression alone ECA-109 cell line? Does it increase? Similarly, in siMap3k7 ECA-109 cells, does endogenous PLCE1 S1060p reduce?</p></disp-quote><p>Thank the referee for these critical comments. During the revision, we examined whether TAK1 overexpression or knockdown affects endogenous p-PLCE1 S1060 in ECA-109 cells. Our data showed that TAK1 overexpression induced an increase in p-PLCE1 S1060, whereas TAK1 knockdown resulted in a decrease in p-PLCE1 S1060. These data were presented in Figure S6A, B.</p><disp-quote content-type="editor-comment"><p>(2) The authors show that using TAK1 inhibitors cannot completely abolish all the phosphorylation of PLCE1 S1060 in cells and mice. Does it mean some other potential kinases also target PLCE1 S1060?</p></disp-quote><p>Thank the referee for this insightful comment. As mentioned by the referee, TAK1 inhibitors cannot completely abolish all the phosphorylation of PLCE1 S1060 in cells and mice. Therefore, it is likely that some other potential kinases also target PLCE1 S1060, we added this notion in the Discussion in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(3) PLCE1 S1060A completely bans the migration and invasion regulation function of TAK1 (Figure S10), indicating that PLCE1 S1060 is a very unique downstream target of TAK1 in migration and invasion regulation in the ECA-109 cell line. As a MAP3K, TAK1 was documented to regulate migration and invasion through multiple signal transduction pathways such as IKK, JNK, p38 MAPK, et al. Have the authors ever tried to test the effect of overexpression/knockdown of TAK1 on a few of these pathways in the ECA-109 cell line?</p></disp-quote><p>Thank the referee for these constructive comments. During the revision, we analyzed the effects of TAK1 on IKK, JNK, p38 MAPK, and ERK. Our data showed that TAK1 positively regulates these signal transduction pathways. For example, TAK1 overexpression increased p-IKK, p-JNK, p-P38 MAPK, and p-ERK in ECA-109 cells, whereas TAK1 knockdown decreased these protein levels. Although these pathways are affected by TAK1, with respect to cell migration and invasion, PLCE1 is likely a unique substrate of TAK1 in migration and invasion regulation in ECA-109 cells. We added these contents in the Results section in revised manuscript, and these data were presented in Figure S12A-D.</p><disp-quote content-type="editor-comment"><p>(4) Does TAK1 only catalyze the S1060 site on PLCE1 protein?</p></disp-quote><p>Thank the referee for this insightful comment. Currently, we just found TAK1 catalyze the S1060 site on PLCE1 protein, which cannot exclude the possibility that TAK1 also phosphorylates other residues on PLCE1 protein.</p><disp-quote content-type="editor-comment"><p>(5) Is there any PLCE1 S1060 point mutation existing in ESCC patients? Does it influence the prognosis of ESCC patients?</p></disp-quote><p>Thank the referee for this critical and constructive comment, which would further strengthen the significance of current study. However, we are facing a shortage of enough patient tumor samples for addressing this very important issue.</p><disp-quote content-type="editor-comment"><p>(6) What's the effect of TAK1 inhibitor on mice body weight?</p></disp-quote><p>Thank the referee for this critical comment. Since body weight is an important parameter, we measured mouse body weight during the whole experiments. The results showed that the body weight growth rate is not affected by TAK1 inhibitor, Takinib. These data were included in the revised manuscript as Figure S20A.</p><disp-quote content-type="editor-comment"><p>(7) For the control groups of the mouse xenograft tumor model in Figures 6 vs 7, why does the number of metastases behave so differently?</p></disp-quote><p>In Figure 6, the control mice were administered with ECA-109 cells via tail vein injection, mice were then treated with vehicle (saline). As for the control mice in Figure 7, they were administered with ECA-109 cells via tail vein injection. It should be mentioned that these cells were transduced with control lentivirus. Due to these differences, therefore, these two control mice have different number of metastases.</p></body></sub-article></article>